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If there is one topic that has drastically affected human society in the last decades, it 
definitely is the global pandemic caused by COVID-19. As a result, there has never existed 
a higher desire to create a vaccine in order to combat any virus in the entire world. 
Therefore, this academic paper is going to analyze the valuation of Pfizer Inc., which was 
the first company that has discovered and fabricated a vaccine against the COVID-19 
virus.  
Firstly, we are going to shortly explain the methodology utilized in order to analyze the 
valuation of Pfizer. This will be followed by the description of the pharmaceuticals & 
biotechnology sector through Porter´s Five Forces Model, the PESTEL analysis as well as 
a comparison between the most important COVID-19 manufacturers. Next, the paper will 
enter the financial analysis of the company, which has been mainly divided into three 
sections, namely the key financial ratios of the enterprise, the relative valuation by 
examining the key multiples and the long-term trends of the firm by reviewing their 
performance of the last fifteen years. Following that, we are going to calculate Pfizer´s 
valuation per share for the next five years, and hence compare it to the firm´s market 
valuation to determine whether the firm is overvalued or undervalued. Lastly, we are going 
to briefly indicate the limitations we must face when calculating the company´s value and 
consequently explain the conclusion of the academic bachelor thesis. 
 
3. Methodology 
Regarding section four and five from the index, most of its analysis is based on the 
European Union report regarding the post-COVID-19 value chains (Raza et al., 2021), 
the book “Organization theory and design” (Daft and Armstrong, 2008), and Pfizer´s 
annual report from 2020, in order to get a better understanding of the pharmaceutical 
industry and Pfizer´s position within it. When it comes to the different vaccine 
competitors, the paper especially utilized medicine websites such as “Yale Medicine” or 
the US government Center for Disease Control and Prevention, to have a specific 




Concerning the financial analysis composed by section seven, eight, and nine, we have 
employed five main bibliographies, namely “Valuation for M&A: Building and Measuring 
Private Company Value” (Mellen and Evans, 2018); “Navigating the Business Loan: 
Guidelines for Financiers, Small-Business Owners, and Entrepreneurs” (Glantz, 2014); 
“The Art of Company Valuation and Financial Statement Analysis: A Value Investor's 
Guide with Real-Life Case Studies” (Schmidlin, 2014); the Corporate Finance Institute 
webpage and finally “Valuation: Theories and Concepts” (Kumar, 2015). With respect to 
that, the most used source has been Kumar´s book, mainly because it displayed not only 
theoretical concepts, but also applied lots of practical cases in order to better understand 
and analyze Pfizer´s values. 
Lastly, the paper used the same bibliography for the valuation calculation as in the 
financial analysis part, with the addition of the book “Fusiones, adquisiciones y valoración 
de empresas” (Mascareñas, 2011), as well as “Corporate Valuation : Measuring the Value 
of Companies in Turbulent Times” (Massari et al., 2016). in order to better determine 
whether Pfizer´s valuation has been overestimated or not. 
 
4. Industry description 
It is undeniable to state the fact that COVID-19 has completely changed our perception 
of our common everyday activities. The virus has led to terrible consequences such as 
more than 2,5 million deaths in the world and an upcoming financial crisis. To be exact, 
several experts claim that this “economic impact of COVID-19 will cut deeper than any 
recession in living memory” (Bremmer, 2020). Nevertheless, there is one sector that will 
benefit from this global pandemic, namely the pharmaceuticals & biotechnology sector. 
In fact, the pharmaceutical market showcases an ongoing exponential increase in 
revenues from 2001 till 2020 (IQVIA, 2021), as we can see in Table 1. With compliance 
to that, the “global pharmaceutical manufacturing market size was valued at USD 
324.42 billion in 2019 and is expected to grow at a compound annual growth rate (CAGR) 
of 13.74% from 2020 to 2027” (Grand View Research, 2021). In other words, we can 
characterize the industry as an attractive and fiercely competitive one, in which 
innovation through heavy R&D investments are key in order to develop a competitive 
advantage (EFPIA, 2020). 
7 
 
Regarding the products of the market, we must differentiate between two main 
pharmaceutical drugs, namely the brand-name and the generic drug. The brand-name 
drug is a “drug sold by a drug company under a specific name or trademark and that is 
protected by a patent” (HealthCare.gov, 2021). Concerning the second medicine, it is the 
generic drug, which “is a medication created to be the same as an existing approved 
brand-name drug in dosage form, safety, strength, route of administration, quality, and 
performance characteristics” (FDA, 2021). In other words, the “difference between a 
brand-name product and a generic one is designed to be transparent” (Mogalian and 
Myrdal, 2021), because “once the patent life expires on a brand-name drug product, it is 
eligible to be made into a generic drug.” (Mogalian and Myrdal, 2021). Concerning the 
production, it depends on the type of pharmaceutical drug, “the production process may 
include advanced IT elements such as software development or more general industrial 
competencies” (Raza et al., 2021). 
With respect to that, the pharmaceuticals & biotechnology sector is characterized by its 
patents. Their main attribute is that they possess a property right granted to an inventor 
for an invention, which excludes others from making, using, or selling the creation for a 
specific period of time (Stedeford, 2009). Having said that, the particularity of the 
pharmaceutical sector is that, unlike other industries, the patent usually is the product 
itself (Kumazawa, 2017). When it comes to the duration, pharmaceutical companies 
receive 20 years for their patents, but because R&D can endure up to 15 years alone this 
inevitably leaves the drugs with a very short time frame to operate, plus once the 20-year 
exclusivity period is over, generic competitors can enter the market and compete with the 
branded drug on price (Nawrat, 2019). 
Lastly, we must highlight how the COVID-19 health crisis has reshaped the 
pharmaceuticals & biotechnology sector. For example, Europe´s “imports of protective 
garments and similar products grew by 185% (EUR 18.7 billion), an increase which can 
be largely attributed to the 1462 % growth in facemask imports from EUR 1.1billion to 
EUR 17.2billion” (Raza et al., 2021). According to that, China has proven to be one of 
the countries that benefitted the most from the virus, given the fact that the “EU and US 
dependence on China only increased during the pandemic” (Zeiger, 2020). Nevertheless, 
it would be an error to believe that the pharmaceuticals & biotechnology sector will 
become one-sided, as several countries are seeing the opportunities this market has to 
offer and as a result “tend to be both importers and exporters of PPE (Protective Personal 
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Equipment) and medical devices” (Raza et al., 2021).Table 1: Revenue of the 
worldwide pharmaceutical market  
 
 
Source: (IQVIA, 2021)  
 
Table 2: Annual growth of pharmaceutical R&D spending in Europe and the U.S 
 
Source: (EFPIA, 2020) 
 
 
4.1 Porter´s Five Forces Analysis 
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Concerning Porter´s 5 Forces, it is a model utilized in order to “determine an industry’s 
long-term profitability” (Marburger, 2012). In this case, we have divided the different 
forces as follows: 
 The Threat of New Entrants:  
The key to understand here, is that this force mainly depends “on the amount and 
extent of potential barriers” (Daft & Armstrong, 2008) to entry. With respect to 
that, the pharmaceutical & biotechnology sector is composed by “high costs 
required to enter the industry” (Kasapi & Mihiotis, 2011), such as CAPEX or 
R&D. Furthermore, it is also quite difficult for new entering enterprises to access 
the necessary distribution channels (Kasi, 2017). Therefore, we can claim that the 
threat of new entrants is relatively low. 
 The Power of Suppliers: 
Regarding the power of suppliers, it is affected by powerful suppliers that “can 
charge higher prices, limit services or quality, and shift costs to their customers, 
keeping more of the value for themselves” (Daft & Armstrong, 2008). However, 
this threat is very low for Pfizer, given the fact that they are not too dependent on 
specific suppliers because they have “supplier management activities in place to 
monitor supply channels and to take action as needed to secure necessary 
volumes” (Pfizer, 2021). 
 The Power of Buyers: 
An example to simplify this force is, when “the number of buyers of a product or 
service increases, the bargaining power of any individual buyer decreases” (Evans 
and Neu, 2008) and vice versa. In general terms, customers are not too aware of 
the differentiation and cost of pharmaceutical products (Kasi, 2017), and as a 
consequence do not possess enough power to affect the pricing of these products. 
However, the government is a key player that can influence the pricing of Pfizer´s 
Covid-19 vaccines in the upcoming future, due to the possibility of waiving the 
patent protections (Macias et al., 2021) caused by the pandemic. Therefore, we 
can state that the power of buyers is moderate, because of the fact that citizens are 
less powerful, and governments can clearly affect the final price of Pfizer´s 
products. 
 
 The Threat of Substitutes: 
10 
 
A substitute is known to be a good or service that satisfies the same need as the 
product it is emulating and as a result, it “can reduce industry attractiveness and 
profitability because they put a constraint on price levels” (Hollensen, 1998). In 
this case, Pfizer as well as other pharmaceutical giants “are under intense pressure 
from generic competition as patents on numerous popular drugs have expired in 
recent years” (Daft & Armstrong, 2008). Nonetheless, this only applies to certain 
older products that are being replaced through new innovation, whereas there is 
still a significant lack of availability of substitutes for health-related products in 
the pharmaceuticals & biotechnology sector (Kasi, 2017). In other words, the 
threat of substitutes is moderate.  
 Rivalry among Existing Competitors: 
With reference to the last force, it is “influenced by the preceding four forces” 
(Daft & Armstrong, 2008) and as a result, it measures the power of competitors 
in its given industry. When it comes to Pfizer, they showcase a market share of 
12.08% in the first quarter of 2021 as we can see in Figure 1, which is a good 
result considering how fiercely competitive the pharmaceuticals & biotechnology 
sector actually is. In addition, other key competitors are Abbott Laboratories and 
Johnson & Johnson with 11,21% and 24,4% market share respectively 
(CSIMarket, 2021). Therefore, we can verify that Pfizer´s “business is conducted 
in intensely competitive and often highly regulated markets” (Pfizer, 2021), which 
implies that the rivalry among competitors is high. 




5. Pfizer´s PESTEL Analysis 
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In order to determine Pfizer´s position in the pharmaceuticals & biotechnology sector, we 
are going to employ an analysis through the PESTEL model. Regarding the PESTEL 
analysis, it is a tool used to examine how political, economic, social, technological, 
environmental, and legal factors affect an enterprise in their industry (Fosher, 2018). The 
different factors have been analyzed in the following section: 
 Political 
When it comes to political factors, Pfizer is subject to extensive regulation by 
government authorities in the countries they operate in, which includes laws and 
regulations that must be fulfilled in order to prevent penalties such as orders to 
stop non-compliant activities, criminal charges, warning letters, etc. (Pfizer, 
2021). In other words, Pfizer must comply with all the given jurisdictions of 
different countries to not harm the firm´s compliance and reputation.  
 Economic 
Being a multinational enterprise that runs its operations in the entire world, Pfizer 
must be susceptible to several economic risks, such as “currency fluctuations, 
capital and exchange controls, and global economic conditions” (Pfizer, 2021). 
Furthermore, the company must maintain efficient productivity in order to 
minimize operational costs and increase sales.  
 Social 
According to Pfizer´s environmental, social, and governance (ESG) report, the 
company is of the mindset that if they “abide by core values such as equity and 
courage and make ethical decisions” (MarketScreener, 2021) this will result in a 
competitive advantage for them. Furthermore, Pfizer was the first company to 
issue a sustainable bond in 2020 in order to support vulnerable citizens to “address 
global public health emergencies” (Pfizer, 2021). 
 Technological 
Concerning the technological factors, Pfizer heavily relies on sophisticated 
information technology systems in order to prevent breaches of its information 
security (Pfizer, 2021). Moreover, they implement digital technology to assist 
their commercial, manufacturing, and R&D operations (Pfizer, 2021).  Lastly, and 
most importantly, the company especially invested in technology in order to 
achieve advances in both biological science and digital technology to enhance the 




With reference to the environmental factors, Pfizer claims in their annual reports 
that their “operations are affected by national, state and/or local environmental 
laws” (Pfizer, 2021). To be more concrete, the company is well aware of the 
importance of maintaining a healthy environmental reputation, and as a result, 
they invested “$42 million in environment-related capital expenditures and $120 
million in other environment-related expenses (Pfizer, 2021). 
 Legal 
Concerning the legal aspects, there is rarely an industry that is more involved in 
legal procedures than the pharmaceuticals & biotechnology sector. As a matter of 
fact, Pfizer engages in “various legal proceedings, including patent litigation, 
product liability and other product-related litigation, including personal injury, 
consumer, off-label promotion, securities, antitrust and breach of contract claims” 
(Pfizer, 2021). 
 
6. Vaccine COVID-19 competitors 
We will compare the four most common types of COVID-19 vaccines, by taking a closer 
look at their technology used to produce them, their effectiveness, and their perceived 
security from the public. To be more specific, this section will analyze the vaccines of 
Pfizer, Moderna, AstraZeneca, and Johnson & Johnson. 
Regarding Pfizer and Moderna, both utilize mRNA technology for their vaccines, 
whereas AstraZeneca´s and Johnson & Johnson´s vaccines are created through the 
traditional approach (Smith, 2021). With respect to that, both productions have their pros 
and cons. For one, the mRNA vaccine is a revolutionary new type of vaccine that teaches 
our cells how to produce antigens, whereas with the conventional approach the antigens 
are injected into the patients (CDC, 2021). Nonetheless, mRNA vaccines need colder 
temperatures in order to be stored. For instance, Moderna´s and Pfizer´s vaccines must be 
stored at -4°F and -94°F, respectively, whereas Johnson & Johnson´s and AstraZeneca´s 
vaccines are easier to store at temperatures between 36°F and 46°F (Smith, 2021). In 
addition to that, mRNA vaccines also exhibit more problems when it comes to shipping 
because they need colder temperatures than traditional vaccines. To be more specific, 
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Pfizer had to transport their vaccines in ultra-cold temperature-controlled units at -94 
degrees Fahrenheit (Katella, 2021). 
Next, we must view the respective effectiveness of the four different Covid-19 vaccines. 
The most effective vaccine so far has been Pfizer-BioNTech which has reported an 
effective rate of 95% to prevent COVID-19 and 100% effective at preventing severe 
diseases (Katella, 2021). The second most effective vaccine is Moderna with a rate of 
94,1% to generally prevent COVID-19, however, this value drops to 86,4% effectiveness 
for those patients that are 65 years old or older (Katella, 2021). Regarding the traditional 
vaccines, AstraZeneca and Johnson & Johnson occupy third and fourth place and exhibit 
an effective rate of 76% and 66% respectively. In other words, mRNA vaccines are more 
effective than conventional vaccines.  
Lastly, we must analyze the popularity and perception of the safety of the respective 
vaccines. In Figure 2 we can see a direct safe perception comparison between Pfizer-
BioNtech, Oxford-AstraZeneca, and Moderna, which clearly shows that the mRNA 
vaccines are clearly more popular than the traditional Oxford-AstraZeneca vaccine 
alternative. To be more concrete, this result makes complete sense, given the fact that as 
our analysis has shown, mRNA vaccines are more secure and efficient to battle COVID-
19, and as a consequence, their popularity increases. 
Figure 2: Vaccines´creation is viewed differently by the public  
 
Source: (Armstrong, 2021) 
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Now that we have investigated and acknowledged the main characteristics of the 
pharmaceuticals & biotechnology sector, we will broaden the paper by analyzing the main 
financial aspects in order to determine the valuation of Pfizer Inc. 
 
7. Financial Ratios 
7.1 Short-term activity 
Firstly, we will start analyzing Pfizer´s inventory turnover, which is key to measure “the 
company’s inventory management efficiency by calculating the number of times the 
average inventory is converted into receivables or cash during the year” (Mellen & Evans, 
2018). When taking a glance at Pfizer´s inventory turnover figures, we can clearly identify 
that this number has continuously dropped from 2016 till 2020. This is due to two 
different reasons. Firstly, their cost of sales dropped greatly from $12.329 million in 2016 
to $8.692 million in 2020. The second reason is the increase of their inventories on hand, 
to be more exact their inventories increased from $6.783 million to $8.046 million from 
2016 to 2020. These numbers are a bad sign because a “poor inventory turnover could 
cripple the profitability” (Mellen & Evans, 2018), due to the fact that lower cost of sales 
indicate that they have sold fewer products, which can be validated by the fact that their 
inventories on hand have increased. In other words, they are stocking up inventory 
because they are not able to sell as much as they want to. When we take a closer look at 
the pharmaceuticals & biotechnology sector, we can see that it exhibits a stable inventory 
turnover with a value of 2,41 in 2016 and 2020 respectively. Plus, if we look at Figure 3, 
we can state the fact that except for 2019, the sector had a similar inventory turnover 
value year after year. Inevitably, this means as shown in Figure 4, that Pfizer has a higher 
average inventory processing period than the sector, which indicates “that the company 
may be carrying excessive inventory” (Mellen & Evans, 2018). Nevertheless, we can all 
agree that 2020 has been a quite unique year which has caused several issues such as 
“impacts due to travel limitations and mobility restrictions; manufacturing disruptions 
and delays; supply chain interruptions” (Pfizer, 2021) and therefore it is more than likely 






Figure 3: Inventory Turnover Sector Comparison 
 
Source: Calculation from Pfizer´s Financial Statements 
 
Figure 4: Avg. Inventory Processing Period Sector Comparison 
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The next ratio to be examined is the receivables turnover ratio, which is calculated by 
dividing the company´s revenues by its accounts receivables. The idea is that the “higher 
the turnover of receivables, the shorter the time between the recognition of revenue and 
cash collection” (Mellen & Evans, 2018). In this case, Pfizer showcases a solid 
receivables turnover when we compare their figures to the ones of the pharmaceuticals & 
biotechnology sector from 2016 to 2020 in Figure 5. To be more concrete, Pfizer exhibits 
a higher receivables turnover from 2016 till 2019, except for the year 2020. Nevertheless, 
we can state the fact that 2020 is only a bump in the road for Pfizer, and we can therefore 
declare that they will keep showing a better receivables turnover than their competitors 
in the future. Hence, this is a great sign for Pfizer, given the fact that a greater ratio than 
the sector will imply a lower average receivable collection period than their competitors. 
In other words, “the sooner the firm is able to collect its accounts receivable, the firm 
would be able to pay off its own current liabilities” (Kumar, 2015). 
Figure 5: Receivables Turnover Sector Comparison 
 
Source: Calculation from Pfizer´s Financial Statements 
Concerning Pfizer´s payables turnover, the first thing to notice is that there is a clear 
downward trend from 2016 to 2020, with values of 2,72 and 2,02 respectively. This ratio 
is composed of “dividing cost of goods sold by average inventory at the end of the 
financial year” (Malingu Achode and Rotich, 2016) and it helps to measure the time it 
takes a business to pay its creditors (Glantz, 2014). In this case, Pfizer is showcasing 
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because “a declining payables turnover ratio indicates a larger accumulation over a longer 
period of spontaneous working capital financing provided by trade creditors” (Richards 
and Laughlin, 1980), in other words, they need longer time to pay-off their suppliers. This 
situation is reflected when we compare Pfizer´s average payables payment period to its 
sector. In fact, Pfizer´s average payables payment period has been quite stable from 2017 
to 2019, except for 2020, which demonstrates that Pfizer has what it takes to turn this 
situation around and return to its stable pre-pandemic numbers. In addition to that, Pfizer 
claims in their 10-k that they have enough supplier management activities in place to 
ensure that their suppliers will be paid back in time. 
Regarding Pfizer´s working capital turnover, we can see that they had better values than 
the sector from 2016 to 2018. Nevertheless, in 2019 its working capital was negative, 
which was consequently improved to a value of 4,58 in 2020, which is only slightly below 
the average of the pharmaceuticals & biotechnology sector. This is a great indicator, that 
shows that Pfizer is on its path to surpass the working capital turnover of its competitors 
in the near future. Furthermore, having “sufficient working capital is essential to meet 
operating needs along with supplier and short-term debt obligations” (Glantz, 2014). 
Therefore, we can claim that Pfizer is on a good path. 
Last but not least, we must talk about Pfizer´s operating cycle as well as its cash 
conversion cycle. With respect to the operating cycle, it is the sum of the average 
inventory processing period and the average receivable collection period. Pfizer 
showcases an increasing operating cycle from 2016 to 2020 in Figure 6, which is mostly 
caused as we explained before by the increase of its inventory on hand and the reduction 
of cost of sales. However, it is quite likely that their sales will increase in 2021, due to 
their COVID-19 vaccine. That´s why they will exhibit a higher inventory turnover and as 
a consequence a lower average inventory processing period, which will translate into a 
lower operating cycle. Concerning Pfizer´s cash conversion cycle, it “shows how long the 
capital is actually tied up in inventory and receivables less outstanding payables” 
(Schmidlin, 2014). In other words, it can indicate the level of a company´s liquidity, 
effective management of inventory, and its credit sales. The company clearly exhibits an 
increasing trend in its cash conversion cycle in comparison to its sector, which is not a 
good sign. However, as we have explained before, Pfizer has clearly suffered in 2020, as 
we have seen reflected in its lower sales, therefore we can clearly say that Pfizer has a 
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great potential to recover from last year and exhibit the same numbers as it has had in 
prior periods from 2016 to 2018. 
 
Figure 6: Operating Cycle Sector Comparison 
 
Source: Calculation from Pfizer´s Financial Statements 
Figure 7: Cash Conversion Cycle Sector Comparison 
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7.2 Long-term activity 
Regarding Pfizer´s long-term activity is key in order to determine the company´s long-
term projection in a fiercely competitive industry as the pharmaceuticals & 
biotechnology one. 
First of all, we will start analyzing Pfizer´s net fixed asset turnover. The main reason for 
that is because of the fact that investments in property, plant, and equipment are crucial 
in order to reduce cash flows once the company performs an investment. “As a result, 
cash generated by productive assets must offset initial investment outflows, producing a 
positive net present value” (Glantz, 2014) and consequently, it will exhibit the “cash flow 
quality and sustainability. (Glantz, 2014). In this case, both Pfizer and the 
pharmaceuticals & biotechnology sector showcase fluctuations in their results from 2016 
till 2020. However, we can clearly state that the pharmaceuticals & biotechnology sector 
displays higher numbers in the time period from 2016 till 2020. Therefore, we can claim 
that Pfizer´s competitors are investing more into property, plant and equipment and as a 
consequence perform higher revenues than them. That being said, the main reason for 
Pfizer´s low value of 3,01 in 2020 is mainly because they have suffered a reduction in 
revenues of 19,02% and we can all agree that this is situation is going to be quite different 
in 2021 thanks to their new Covid-19 vaccine. For that reason, it is quite likely that Pfizer 
is going to perform better in terms of its sales, which is going to translate into a higher 
net fixed asset turnover for the upcoming future.  
Table 3: Net Fixed Asset Turnover 
Net fixed asset turnover 2016 2017 2018 2019 2020 
Pfizer 3,97 3,79 4,01 3,71 3,01 
Pharma. & Biotech. 4,20 4,08 4,22 4,11 4,07 
Source: Calculation from Pfizer´s Financial Statements 
Secondly, we are going to take a closer glance at Pfizer´s total asset turnover. In this case, 
a high “asset turnover means that capital flows back quickly into the business and less 
capital is therefore needed altogether in order to achieve a certain business volume” 
(Schmidlin, 2014). Here we must concede, that even though Pfizer displays quite stable 
figures from 2016 to 2019, their numbers are below the pharmaceuticals & biotechnology 
sector. In addition to that, Pfizer once again shows that 2020 has not been their best year. 
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Nevertheless, this decrease was mainly caused due to Pfizer´s decrease in sales, which 
represents the numerator of the total asset turnover. Therefore, we can allege the point 
that Pfizer will increase its total asset turnover during this upcoming year 2021, due to an 
increase in its sales because of their launch of the COVID-19 vaccine. 
Table 4: Total Asset Turnover 
Total asset turnover 2016 2017 2018 2019 2020 
Pfizer 0,31 0,31 0,34 0,31 0,27 
Pharma. & Biotech. 0,42 0,41 0,46 0,40 0,40 
Source: Calculation from Pfizer´s Financial Statements 
Lastly, we must focus on the company´s equity turnover, in order to examine “the 
efficiency with which management is using equity to generate revenue” (Bragg, 
2020). In this case, we can see that Pfizer overall exhibited an equity turnover over 80% 
in 2016, 2018 and 2019. This time we have two exceptions. The main reason for the lower 
value in 2017 is due to an increase of the company´s equity of 19,76%. However, Pfizer 
reacted and decided to reduce its equity amount by 11,08%, which inevitably led to a 
higher equity turnover for the two following years. Regarding the lower equity turnover 
of 2020, the company experienced as mentioned before a significant reduction in its sales 
of 19,02% and as a result exhibits a value of 0,66. 
Table 5: Equity Turnover 
Equity turnover 2016 2017 2018 2019 2020 
Pfizer 0,89 0,74 0,85 0,82 0,66 
Pharma. & Biotech. 1,12          1,17 1,41 1,28 1,32 
Source: Calculation from Pfizer´s Financial Statements 
7.3 Liquidity 
Analyzing a company´s liquidity is one of the most important steps in a company´s 
valuation. The main reason for that is because it explains the company´s short-term 
funding, plus it also asserts “whether or not a business is carrying too many current assets 
on its balance sheet” (Schmidlin, 2014).  
Firstly, we must analyze Pfizer´s current ratio to examine “the relationship between 
current assets and current liabilities” (Kumar, 2015). As we can see, Pfizer exhibits an 
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increase of 0,88 in 2019 to a value of 1,35 in 2020. This is great news, due to the fact that 
the pharmaceuticals & biotechnology sector has decreased its current ratio during those 
two years. To be exact, Pfizer unlike its competitors, was able to reduce its current 
liabilities during 2020. That´s why they managed to reach pretty much the same current 
ratio with a value of 1,35 as its sector which had a value of 1,37. 
Table 6: Current Ratio 
Current ratio 2016     2017     2018     2019     2020     
Pfizer 1,25 1,35 1,57 0,88 1,35 
Pharma. & Biotech. 2,10 1,82 1,73 1,57 1,37 
Source: Calculation from Pfizer´s Financial Statements 
The next step is to examine the quick ratio, which determines if a firm is able to “pay off 
short-term obligations without depending on sale of inventories” (Kumar, 2015). In this 
case, all values for Pfizer are below one from 2016 to 2020, which indicates that the 
company heavily relies on its inventory sales. However, the pharmaceuticals & 
biotechnology sector quick ratio has a decreasing trend from 2016 to 2020, which shows 
that the overall industry is becoming more reliant on its inventory sales.  
Table 7: Quick Ratio 
Quick ratio 2016     2017     2018     2019     2020     
Pfizer 0,84 0,93 0,84 0,50 0,78 
Pharma. & Biotech. 1,64 1,41 1,28 1,18 0,96 
Source: Calculation from Pfizer´s Financial Statements 
Finally, we have to analyze the cash ratio. The main reason for the usage of this ratio is 
because of the fact that it “is the best indication of a company's ability to cover its short-
term obligations when in an emergency” (Affandi, Sunarko and Yunanto, 2019). At first 
one might think that Pfizer does not have enough cash to finance its short-term debt in 
comparison to its competitors. However, this is not completely true, because the industry 
exhibits a negative cumulative growth rate of -14,96% from 2016 to 2020, whereas Pfizer 
just showcases a negative cumulative growth rate of -3,78% during those five years. 
Obviously having a negative growth rate is not the best scenario, but the good news is 
that Pfizer´s competitors are experiencing worse cash results year after year. In addition 
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to that, Pfizer have reduced their cash ratio in 2019 and 2020 mainly because they 
engaged in fewer short-term investments than from 2016 to 2018. 
Table 8: Cash Ratio 
Cash ratio 2016     2017     2018     2019     2020     
Pfizer 0,57 0,66 0,59 0,26 0,47 
Pharma. & Biotech. 1,23 1,01 0,90 0,81 0,58 
Source: Calculation from Pfizer´s Financial Statements 
7.4 Solvency 
Now we will analyze several financial leverage ratios in order to examine whether 
Pfizer has the “capacity to meet interest and principal payments in the long term” 
(Kumar, 2015). 
Firstly, we will take a closer look at Pfizer´s debt-to-equity ratio, which as the name 
already indicates is just calculating the total debt by the total company´s equity. In this 
case, Pfizer is showing great results from 2016 to 2020. To be exact, they manage to 
decrease from 0,71 in 2016 to 0,63 in 2020, which means that the company was able to 
reduce its risk over this five-year span by not growing through debt. In addition to that, 
the pharmaceuticals & biotechnology sector is exhibiting a clear increase in its debt-to-
equity ratio by increasing from 0,84 to 1,2 in only five years. In other words, Pfizer´s 
competitors are indicating clear signs of risk, given the fact that they have been quite 
aggressive in financing their growth through debt (Young, 2020). The key aspect to 
highlight here is that Pfizer has been able to reduce risk over the years, unlike most of 
their other competitors. 
Table 9: Debt-to-Equity  
Debt to equity 2016     2017     2018     2019     2020     
Pfizer 0,71 0,61 0,66 0,83 0,63 
Pharma. & Biotech. 0,84 0,94 1,00 1,12 1,20 
Source: Calculation from Pfizer´s Financial Statements 
Secondly, we will take a closer glance at the debt-to-capital ratio, which is based on the 
total debt divided by the sum of total debt and equity. In this case, we can clearly see that 
Pfizer´s values are below the sector´s values each year, which indicates that Pfizer is less 
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risky than its competitors in the pharmaceuticals & biotechnology sector. The main 
reason that Pfizer is less risky, is because they must pay back less debt than their 
competitors, which can be validated by the debt-to-equity ratio we calculated before that 
demonstrated that Pfizer relies less on debt financing than their competitors. However, 
there are two sides to the same coin, because debt is a more affordable source to finance 
operations than shareholder´s equity. In addition to that debt investors usually ask for 
higher returns due to several risks, whereas debt usually has lower rates (Berman and 
Knight, 2009). 
Table 10: Debt-to-Capital  
Debt to capital 2016     2017     2018     2019     2020     
Pfizer 0,41 0,38 0,40 0,45 0,39 
Pharma. & Biotech. 0,46 0,48 0,50 0,53 0,54 
Source: Calculation from Pfizer´s Financial Statements 
Concerning Pfizer´s debt-to-assets ratio, the first thing to notice is that Pfizer´s numbers 
are lower from 2016 to 2020 than its competitors. In this case, the ratio “indicates the 
percentage of assets that are being financed with debt” (CFI, 2021). In other words, 
Pfizer´s lower ratios compared to its adversaries mean a lower leverage degree, which 
implies less risk to invest in the company. 
Table 11: Debt-to-Assets 
Debt to assets 2016     2017     2018     2019     2020     
Pfizer 0,25 0,25 0,26 0,31 0,26 
Pharma. & Biotech. 0,31 0,32 0,32 0,35 0,36 
Source: Calculation from Pfizer´s Financial Statements 
Next, we must compare Pfizer´s financial leverage with its competition. The calculation 
is composed of total assets divided by total equity and its intention is to show the rate at 
which assets have been financed by the company´s shareholders. (Bragg, 2020). As we 
can see, Pfizer exhibits except for 2016, lower values than its competitors, which implies 





Table 12: Financial Leverage 
Financial leverage 2016     2017     2018     2019     2020     
Pfizer 2,88 2,41 2,51 2,65 2,44 
Pharma. & Biotech. 2,67 2,89 3,08 3,18 3,34 
Source: Calculation from Pfizer´s Financial Statements 
The fifth ratio in this section is the interest coverage ratio. Its purpose is to measure “the 
firm’s capacity to meet interest payments from its predebt and pretax earnings” (Kumar, 
2015) and it is calculated by diving the company´s EBIT by its interest expense. In this 
case, Pfizer managed to surpass the average of its competitive sector in 2019, but both 
Pfizer and its competitors fell short in terms of their interest coverage ratio due to COVID-
19. However, if we look at the past years we can see that Pfizer´s interest coverage ratio 
had a positive cumulative growth rate of 43,09% from 2016 to 2019, whereas the 
pharmaceuticals industry is showing a decreasing interest coverage ratio year after year. 
That’s why Pfizer has a great potential to surpass the sector´s average interest coverage 
ratio in the near future, which will be great for them because a higher ratio means that the 
company is more likely to pay its debt back (Mellen & Evans, 2018). 
Table 13: Interest Coverage 
Interest coverage 2016     2017     2018     2019     2020     
Pfizer 8,04 10,69 10,03 12,23 6,17 
Pharma. & Biotech. 12,62 10,99 10,29 11,09 7,17 
Source: Calculation from Pfizer´s Financial Statements 
Finally, we will examine the fixed charge coverage ratio to analyze Pfizer´s capacity to 
pay its fixed costs. It is calculated when we divide the sum of EBIT and fixed charges 
before taxes by fixed charges. This ratio is key, due to the fact that fixed charges include 
leases and insurance costs which play crucial roles in the pharmaceuticals & 
biotechnology sector. When we focus on the data from 2016 to 2020, we can see that 
Pfizer managed to surpass the industry average fixed charge coverage ratio in 2019, but 
due to COVID-19 Pfizer´s ratio dropped from 9,88 in 2019 to 4,98 in 2020, which is 
below the average value of its competitors in the sector. Nevertheless, we can clearly see 
that Pfizer showcased an increase over time in its fixed charge coverage ratio before the 




Table 14: Fixed Charge Coverage 
Fixed charge coverage 2016     2017     2018     2019     2020     
Pfizer 6,64 8,76 8,34 9,88 4,98 
Pharma. & Biotech. 10,29 9,13 8,63 9,00 5,90 
Source: Calculation from Pfizer´s Financial Statements 
7.5 Profitability 
The next key aspect that we will focus on is Pfizer´s profitability, in order to measure 
“management’s success at production and expense control, as well as its ability to counter 
economic and industry downturns” (Glantz, 2014). 
The first profitability ratio to be examined is the gross profit margin. It “measures 
production success and is an integral part of the lending toolbox because it is especially 
adept at differentiating between temporary and structural problems” (Glantz, 2014). In 
this case, we can clearly see that Pfizer exhibits positive growth from 2016 to 2019, except 
for the pandemic year 2020. That´s why we can state the fact that once Pfizer recovers in 
2021 it will display a higher gross profit margin than in 2020. 
Secondly, we must focus on the operating profit margin. Its purpose is to show “the 
percentage of profit a company produces from its operations, prior to subtracting taxes 
and interest charges” (CFI, 2021). When taking a closer look, we can witness that Pfizer 
displays a constantly growing operating profit margin except for 2020. This was the year 
in which Pfizer performed its worst operating income, which was especially due to the 
company´s increase in R&D expenses in order to develop a COVID-19 vaccine. 
Therefore, we can claim the same reasoning as before. That is to say, once Pfizer increases 
its sales in 2021 and reduces its R&D expenses now that they have finally come out with 
a new vaccine, it is highly possible that the company will exhibit a greater operating 
margin than in 2020. 
Thirdly we will interpret the net profit margin, which “explains the relationship between 
net income and sales” (Kumar, 2015). The first thing to notice is that Pfizer evidences a 
lot of volatility in this ratio. For instance, in 2017 they managed to reach a net profit 
margin of 40,55%, which was primarily due to a great reduction of Pfizer´s certain asset 
impairments that helped them to accomplish a higher net income that inevitably led to a 
higher net profit margin. The primary reason for the result of 2020, is due to a reduction 
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of sales, an increase in R&D expenses, as a major increase of certain asset impairments. 
All of these different reasons translated into a lower net income, hence a lower net profit 
margin of 22,95%.  
Next, we will examine Pfizer´s Return on Equity, which is calculated by dividing the 
company´s net profit by the shareholders´ equity. This ratio is quite important because it 
“gives investors a figure that can be compared between different companies and 
investment opportunities” (Schmidlin, 2014). In this case, Pfizer shows quite volatile 
results, which are mostly caused due to different net incomes through the years, whereas 
its shareholder´s equity has been quite stable during the last five years. 
Last but not least, we will analyze the Return on Assets, which reflects “the income earned 
per amount invested in the firm” (Kumar, 2015). As we can see, the company´s results 
are also quite volatile during this five-year span. The main ground for this is because once 
again Pfizer´s net income has been quite volatile over the years for the reasons mentioned 
before. However, as long as Pfizer will operate as they have done before the pandemic 
and as a result achieve higher net incomes, they will without a doubt display favorable 
results.  
Table 15: Profitability Ratios 
Profitability 2016     2017     2018     2019     2020     
Gross profit margin 76,66% 78,61% 79,03% 80,25% 79,26% 
Operating profit margin      22,73% 25,92% 26,10% 25,46% 19,47% 
Net profit margin 13,66% 40,55% 20,79% 31,45% 22,95% 
ROE 12,12% 29,88% 17,59% 25,77% 15,21% 
ROA 4,20% 12,40% 7,00% 9,72% 6,23% 
Source: Calculation from Pfizer´s Financial Statements 
7.6 Dupont-Analysis 
Next, we are going to analyze Pfizer´s Dupont model and compare them to two of their 
biggest competitors, namely Johnson & Johnson and Abbott Laboratories. The main 
reason I selected Johnson & Johnson, is because they are not only a fierce competitor in 
the pharmaceuticals & biotechnology sector, but they also developed a Covid-19 vaccine 
that has proven to be quite effective to battle the virus. To be more specific, their vaccine 
“was 85% effective in preventing severe disease and, most importantly, demonstrated 
complete protection against COVID-19 related hospitalization and death as of Day 28” 
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(Liu, 2021). Concerning Abbott Laboratories, they are a strong competitor that 
continuously invest in R&D in order to develop new health care products. As a matter of 
fact, “Abbott Laboratories Net Income in the 1 quarter 2021 grew year on year by 
217.91%, faster than average growth of Abbott Laboratories' competitors of 58.71 %” 
(CSI Market, 2021).  
Regarding the Dupont model, it is “used to examine a firm’s financial statements and 
financial performance” (McGowan et al., 2015) by examining its Return on Equity 
through three different factors. “These factors are operating efficiency, which is measured 
by profit margin, asset efficiency which is measured by total assets turnover, and financial 
leverage which is measured by the equity multiplier” (Kumar, 2015). When taking a 
closer look at the net profit margin, we can clearly see that Pfizer has more operating 
efficiency because they display higher results than their competitors. The main reason for 
this is due to the fact that Pfizer accomplished higher EBIT margins than their competitors 
because Pfizer is more flexible when dealing with their expenses. With reference to the 
asset turnover, as we have already mentioned before in section 7.2 of long-term activity, 
Pfizer exhibits lower values than their average competitors. Nonetheless, this is not the 
case for Johnson & Johnson and Abbott Laboratories, who display higher figures than 
Pfizer and the average of the pharmaceuticals & biotechnology sector. In other words, 
Pfizer has less asset efficiency and is not able to benefit from its assets to generate as 
much revenue as their competition. Thirdly, we can see that from 2018 to 2020 Pfizer´s 
financial leverage is overall higher than Abbott Laboratories’ and lower than Johnson & 
Johnson´s. This implies that Pfizer in comparison to Johnson & Johnson “has been 
financed in a conservative manner, with a large proportion of investor funding” 
(Bragg, 2021) because as shown before in section 7.4, Pfizer relies less on debt 
financing than their competitors. In addition to that, this is exactly the opposite when 
comparing Pfizer to Abbott Laboratories, given the fact that Abbott manifests even lower 
values than Pfizer in their financial leverage. As a consequence of these different results, 
we can clearly state that Johnson & Johnson performed the highest return on equity from 
2018 till 2020 as shown in the Table 16. The main cause for these results is because they 
maintained stable results with almost no volatility in the three-year span, unlike Pfizer 
who exhibited a significant decrease in their asset turnover and their financial leverage. 
Regarding Abbott Laboratories, although we can state that they have performed the 
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lowest return on equity among all three competitors, it is also true that they presented the 
only increasing results from 2018 till 200. 
Table 16: Dupont Model 
 Pfizer Inc. Johnson & Johnson Abbott Laboratories 
 2018    2019    2020 2018 2019      2020 2018 2019 2020 
Net profit margin 20,79% 31,45% 22,95% 18,8% 18,4% 17,8% 7,74% 11,56% 12,99% 
Asset Turnover 0,34   0,31     0,27 0,53 0,52 0,47 0,46 0,47 0,48 
Financial Leverage 2,51   2,65     2,44 2,56 2,65 2,76 2,2 2,18 2,21 
ROE 17,7%  25,8%    15,1% 25,44% 25,38% 23,12% 7,83% 11,84% 13,78% 
Source: Calculation from Pfizer´s, Johnsons & Johnson´s and Abbott Laboratories´ 
Financial Statements 
Figure 8: Return on Equity 
 
Source: Calculation from Pfizer´s, Johnsons & Johnson´s and Abbott Laboratories´ 
Financial Statements 
7.7 Return on Investment 
Another key ratio to analyze is the return on investment (ROI) because it tells us whether 
the company is performing as efficiently as possible with the given assets that have been 
put into the business. First and foremost, we can acknowledge the fact that Pfizer has 
experienced a lot of volatility in terms of their return to investment from 2018 to 2020. 
Although it is true that they managed to have the highest ROI in 2019 in comparison to 
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2020. This is primarily because Pfizer´s EBIT decreased by 53,54% from 2019 to 2020. 
In other words, Pfizer is not showcasing the best values, given the fact that “a higher 
positive ROI is a good thing because it indicates a more lucrative investment” (Fredman, 
2021), whereas Pfizer´s numbers are decreasing. With respect to Johnson & Johnson, we 
can clearly see that overall, they were able to have the highest ROI in the three-year span, 
however, we can also see that the company is exhibiting a downward trend. In reference 
to that, this is not the case for Abbott Laboratories, which shows an increase in its ROI 
even during the Covid-19 crisis. As a result, we can claim that Pfizer is less predictable 
in terms of its return on investment in comparison to Johnson & Johnson and Abbott 
Laboratories. 
Table 17: Return on Investment 
ROI1 2018 2019 2020 
Pfizer 8,3% 11,5% 5,8% 
Johnson & Johnson 12,4% 11,2% 9,5% 
Abbott Laboratories 5,5% 7,0% 7,6% 
Source: Calculation from Pfizer´s, Johnsons & Johnson´s and Abbott Laboratories´ 
Financial Statements 
Figure 9: Return on Investment 
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Source: Calculation from Pfizer´s, Johnsons & Johnson´s and Abbott Laboratories´ 
Financial Statements 
7.8 Cash Flows 
The next important step when evaluating the valuation of a business is to analyze the 
company´s cash flows. In this case, we must differentiate between three different types, 
namely the operating, investing, and financing cash flows. The operating cash flow is 
quite important because it proves “whether a firm’s cash inflows from its business 
operations are sufficient to cover its everyday cash outflows” (Ross et al., 1991). The first 
thing to notice about Pfizer´s operating cash flow is that they are experiencing a 
continuous decrease in their figures. The main reason for this is because of their negative 
changes in working capital over the years. In addition to that, Pfizer also experienced its 
lowest operating cash flow in 2020 because they exhibited the lowest net income from 
continuing operations before allocation to noncontrolling interests, caused by their 
decrease in sales of 19,02% due to the pandemic in 2020. 
Table 18: Operating Cash Flow 
 2016     2017     2018     2019     2020     
Net income2 7.246  21.355  11.188  16.302  7.021  
Deprec. & Amort. 5757 6269 6384 6010 4777 
Changes in WC 2.898  (11.154) (1.745) (9.724) (1.212) 
CFO 15.901  16.470  15.827  12.588  10.586  
Source: Calculation from Pfizer´s Financial Statements 
Secondly, we must analyze Pfizer´s cash flow from investing activities, which is the cash 
that arises from the “cash inflow and outflow generated from sale and acquisition of fixed 
assets” (Gathu, 2018). In this case, we can firmly state that except for 2018, Pfizer 
showcases negative cash flows from investing activities from 2016 to 2017 and 2019 to 
2020. This is a good sign for the company because it implies that Pfizer is constantly 
investing in new activities such as property, plant and equipment, or acquisitions of new 
businesses in order to grow in the future. In addition to that, we can see that Pfizer has 
invested more capital in 2020 because they are planning to recover as soon as possible 
from last year. For instance, Pfizer showcases their highest purchases in PP&E yet 
                                                             
2 Net income from continuing operations before allocation to noncontrolling interests 
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because they are planning to increase their production for Covid-19 vaccines which is 
definitely going to be their cash cow product for 2021. 
 
Table 19: Cash Flow from Investing Activities 
 2016     2017     2018     2019     2020     
Purchases of PPE (1.823) (1.956) (2.042) (2.176) (2.252) 
Purchases of S-t 
investments (15957) (14596) (11677) (6835) (13805) 
Purchases of L-t 
investments (8.011) (3.537) (1.797) (201) (597) 
Other investing 
activities 17.980  15.348  20.041  5.267  12.466  
CFI (7.811) (4.741) 4.525  (3.945) (4.188) 
Source: Calculation from Pfizer´s Financial Statements 
Lastly, we must focus on Pfizer´s cash flow from financing activities, which is mostly 
constituted by “the issuance and repayment of equity, payment of dividends, issuance and 
repayment of debt, and capital lease obligations” (CFI, 2021). In this case, Pfizer is 
exhibiting an increasing trend in its repayments from 2016 till 2020, with the exception 
of 2019, which is the lowest value in terms of the company´s reimbursements. The two 
most significant values of 2020 are, that the company has almost increased its principal 
payments on short-term borrowings by 3 and that they have performed a “decrease in 
purchases of common stock of $8.9 billion” (Pfizer, 2021). Regarding the first point, 
Pfizer decided to reduce the risk due to the pandemic by increasing their short-term 
borrowings instead of utilizing more long-term debt, and as a result, they had to repay 
more short-term borrowings than in prior years. Concerning the second point, it is quite 
surprising that they did not repurchase their shares. Usually, a company buys its own 
shares back as a sign to illustrate “that the company is facing very positive prospects that 
will place upward pressure on the stock price” (CFI, 2021). In accordance with that, Pfizer 
were the first to announce a Covid-19 vaccine, which led to an immense increase in their 
reputation. Therefore, it is quite surprising that they did not take advantage of this 





Table 20: Cash Flow from Financing Activities 
 2016     2017     2018     2019     2020     
Proceeds from S-t 
borrowings 7.472  8.464  3.711  16.455  12.352  
Principal payments on 
S-t borrowings (5.102) (9.990) (4.437) (8.378) (22.197) 
Proceeds from 
issuances of L-t debt 10976 5274 4974 4942 5222 
Principal payments on 
long-term debt (7.689) (6.154) (3.566) (6.806) (4.003) 
Purchases of common 
stock (5.000) (5.000) (12.198) (8.865) — 
      
Cash dividends paid (7317) (7659) (7978) (8043) (8440) 
CFF (8.921) (13.035) (20.441) (8.485) (21.640) 
Source: Calculation from Pfizer´s Financial Statements 
7.9 Free Cash Flow to the Firm 
Lastly, we will focus on the Free Cash Flow to the firm to finish this section. This cash 
flow is composed of the sum of the company´s operating cash flow, its interest expenses 
net of tax, and the deduction of the firm´s capital expenditures. The thing to point out is 
that we can view that Pfizer is exhibiting a decrease in its free cash flow to the firm from 
2018 till 2020. This is not a good sign for the enterprise, given the fact that a lower free 
cash flow implies the company is less capable of paying its expenses and keeping the firm 
afloat (CFI, 2021). In accordance with that, Pfizer has especially suffered in 2020, 
because they exhibited their lowest operating cash flow yet. In addition to that, the 
increase of the company´s CAPEX has also led to a decrease in its free cash flow. 
Nevertheless, it is true that the values for 2020 are no surprise because the company was 
not able to operate on a continuous basis and therefore experienced their lowest operating 
cash flow so far. Moreover, the increase in capital expenditure will generate better 







Table 21: Cash Flow to the Firm 
 2016     2017     2018     2019     2020     
CFO 15.901  16.470  15.827  12.588  10.586  
Interest expense net of 
tax 1.310  1.382  1.233  1.515  1.626  
CAPEX 1.999  2.217  2.196  2.594  2.791  
FCFF3 15.211  15.635  14.864  11.509  9.421  
Source: Calculation from Pfizer´s Financial Statements 
 
In summary, we can state the fact that overall Pfizer´s ratios in 2020 were quite different 
from prior years, which was mainly caused by the effects of the COVID-19 virus. The 
company exhibited lower sales than in its last five years, whereas its competitors managed 
to maintain similar figures from previous years. Therefore, Pfizer showcased worst results 
than its competition in terms of their operating cycle, cash conversion cycle and its 
liquidity. However, Pfizer also proved to be less risky than the average competitor of the 
pharmaceuticals & biotechnology sector, because of the fact that they rely less on debt to 
finance their operations. Additionally, the company also displays solid returns on 
investment in the past three years in comparison to its competitors, which proves the fact 











                                                             
3 Operating Cash Flow + Interest expense net of tax – Capital Expenditure 
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8. Relative Valuation 
8.1 Enterprise Value 
Concerning Pfizer´s enterprise value, it is composed of adding the company´s total equity, 
short-term borrowings, and its long-term debt, as well as the subtraction of the company´s 
cash and its short-term investments. In other words, it is the same as the “equity value 
plus net debt” (Fin-Wiser Advisory, 2018) and its purpose is to quantify “the value of the 
ongoing operations of a firm” (Kumar, 2015). To put it in another way it “can be viewed 
as a theoretical takeover price” (Loughran and Wellman, 2009) of the company. When 
taking a closer look, we can clearly see that Pfizer exhibits its up and downs during the 
last 5 years. From 2016 till 2018 we can see that the enterprise showcases an increasing 
enterprise value with the figures 227.277, 236.623, and 263.9484, respectively. The 
primary reason for this increase is because of the fact that Pfizer incremented the value 
of their share price from 34,06 dollars per share in 2016 to 43,35 dollars per share in 2018, 
which inevitably led to an increase of approximately 8,96% CAGR in the company´s total 
equity during this time span. Nevertheless, the next following years of 2019 and 2020 
highlight a decrease in the company´s enterprise value of 231.815 and 216.485 million 
dollars, respectively. This different scenario can be narrowed down to two different 
reasons. Firstly, the enterprise decreased its price per share significantly in comparison 
with the value of 2018 to $34,10 in 2019 and $33,82 in 2020. Secondly, Pfizer decided to 
reduce their total number of shares of common stock outstanding in 2019 and 2020. To 
be exact, in 2016 and 2017 for example, the company presented 5.951.872.174 and 
5.952.864.751 number of shares of common stock outstanding respectively. This was not 
the case in 2019 and 2020, where Pfizer only showcased 5.547.639.005 and 






                                                             
4 All these figures are given in millions of US dollars 
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Table 22: Enterprise Value 
  2016 2017 2018 2019 2020 
Total equity 203.041  213.124  241.041  189.495  188.870  
Add: S-t borrowings 10.688  9.953  8.831  16.195  2.703  
Add: L-t debt 31.398  33.538  32.909  35.955  37.133  
Total equity and 
debt 245.127  256.615  282.781  241.645  228.706  
Less: Cash  2.595  1.342  1.139  1.305  1.784  
Less: S-t investments 15.255  18.650  17.694  8.525  10.437  
Enterprise value (EV) 227.277  236.623  263.948  231.815  216.485  
Source: Calculation from Pfizer´s Financial Statements 































Figure 11: Total Number of Shares of Common Stock Outstanding 
Source: Calculation from Pfizer´s Financial Statements 
 
8.2 EV to EBITDA 
Next, we will analyze the company´s enterprise value to EBITDA ratio. This ratio is key 
to value different companies in the pharmaceuticals & biotechnology sector, given the 
fact that the “EV/EBITDA ratio is frequently used in cases of depreciation of particular 
relevant intangible assets (copyrights, licenses, patents, goodwill), since they are not 
usually linked with a substantial financial meaning” (Massari et al., 2016). However, this 
ratio also possesses some constraints. To be exact, it does not take into consideration the 
changes in the working capital requirements, nor does it take into account the capital 
investments (Fernandez, 2002). 
Regarding Pfizer, we can claim that they show a lot of volatility, whereas their 
competitors exhibit an ongoing increase from 2016 to 2020. To be more specific, the 
reason for the decrease of the ratio in 2017 is mainly caused by an EBIDTA increase of 
29,75%, while the enterprise value only increased by 4,11% which inevitably led to a 
lower EV/EBITDA ratio. In contrast to that, Pfizer exhibits an increase in the 
EV/EBITDA ratio in 2018, which was only slightly below the ratio of their competition 
with a value of 13,48. This was mainly caused due to the highest enterprise value Pfizer 
has had in the last 5 years with a value of $263.948 million dollars. Nonetheless, Pfizer 
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the 5-year span with a value of 9,17. In reference to that, Pfizer opted for decreasing their 
enterprise value to 231.815 million dollars and was able to increase their EBITDA to 
25.266 million dollars, which was the highest EBITDA from 2016 till 2020. Concerning 
the ratio in 2020, we can witness an increase in the entire pharmaceuticals & 
biotechnology sector, which can be attributed to the fact that both Pfizer and their 
competitors suffered a decrease in their EBITDA´s due to the pandemic. Furthermore, we 
must emphasize the fact that except for 2016 Pfizer is not able to score a higher enterprise 
value to EBITDA ratio than the pharmaceuticals & biotechnology sector, hence we can 
state that Pfizer is undervalued in comparison to its competition.  
Table 23: Enterprise Value/EBITDA 
EV/EBITA 2016 2017 2018 2019 2020 
Pfizer 14,86 11,92 13,48 9,17 15,78 
Pharma. & Biotech. 13,26 14,37 14,94 15,33 19,73 
Source: Calculation from Pfizer´s Financial Statements 

































Source: Calculation from Pfizer´s Financial Statements 
 
8.3 EV to FCFF 
The fourth ratio to analyze is the EV/FCFF 5multiple, which unlike the ratio we have just 
analyzed in section 8.2 includes the company´s capital expenditures, as well as its interest 
expenses net of tax. That is why, this ratio is “regarded as the most complete enterprise 
value ratio, which has, at the same time, the largest deviation, due to its complex 
calculation of the denominator” (Schmidlin, 2014). The first thing we can firmly state is 
that Pfizer, just like their average competitors from the pharmaceuticals & biotechnology 
sector are exhibiting a continuous increase in their EV/FCFF ratio from 2016 to 2020. 
However, it is important to emphasize that Pfizer has surpassed their competitors in 2019 
and 2020, mainly because of their decrease in their free cash flows to the firm during the 
last two years. These results are not favorable for Pfizer, because a lower FCFF multiple 
indicates that the firm is less likely to “expand business operations or pursue other short-
term investments” (CFI, 2021). With respect to that, a lower FCFF value leads to a higher 
EV/FCFF ratio, which means that Pfizer is viewed as a less desirable firm compared to 
                                                             












their competition because in case the company is acquired, it is going to take longer to 
recover the investment due to lower FCFF´s. 
Table 24: Enterprise Value/ Cash Flow to the Firm 
EV/FCFF 2016 2017 2018 2019 2020 
Pfizer 14,94 15,13 17,76 20,14 22,98 
Pharma. & Biotech. 17,22 18,99 17,83 19,89 20,73 
Source: Calculation from Pfizer´s Financial Statements 
Figure 14: Cash Flow to the Firm 
 
Source: Calculation from Pfizer´s Financial Statements 
8.4 Price to FCFE 
Lastly, we are going to analyze Pfizer´s price-to-free-cash-flow-to-equity ratio by taking 
a closer look at its values and consequently comparing them to the pharmaceuticals & 
biotechnology sector. In this case, the free-cash-flow to-equity “is the residual cash flow 
available to shareholders” (Kumar, 2015) and is computed by using the company’s 
operating cash flow, deducting the firm´s capital expenditures, and lastly adding its net 
debt. With respect to that, when taking a closer glance at Pfizer´s FCFE, we can state the 
fact that the company is not able to exhibit constant values from 2016 to 2020. To be 
more specific, Pfizer even shows a negative FCFE in 2020. As a result, this is reflected 
in the price-to-FCFE multiple. In this case, Pfizer manages to obtain an increasing trend 















a good sign for the enterprise, because investors are less likely to trust Pfizer if they are 
not able to achieve a positive FCFE. Nonetheless, we must also concede that 2020 has 
been a unique year that has led to several unexpected outcomes, which indicates that it is 
very unlikely to repeat the same figures in the future.  
Table 25: Price-to-Free-Cash-Flow-to-Equity 
P/FCFE 2016 2017 2018 2019 2020 
Pfizer 12,30 16,06 18,96 10,09 — 
Pharma. & Biotech. 11,99 16,10 21,97 13,17 18,12 
Source: Calculation from Pfizer´s Financial Statements 
 
Table 26: Free-Cash-Flow-to-Equity 
 2016     2017     2018     2019     2020     
CFO 15.901  16.470  15.827  12.588  10.586  
CAPEX 1.999  2.217  2.196  2.594  2.791  
Net Debt 2.573  (1.005) (935) 8.764  (12.755) 
FCFE 16.475  13.248  12.696  18.758  (4.960) 
Source: Calculation from Pfizer´s Financial Statements 
 
In summary, Pfizer showcases completely different results from 2019 to 2020, than from 
2016 to 2018. Firstly, the company exhibits a lower enterprise value in 2019 and 2020, 
which is mainly caused by both a decrease in its price per share, as well as its total shares 
of common stock. Secondly, the company shows a higher EV-to-FCFF than its 
competitors in 2019 and 2020 because of a decrease in its FCFF during those two years, 
which means that the company is viewed as less desirable compared to its competition 
because in case the company is acquired, it is going to take longer to recover the 
investment due to lower FCFF´s. Nonetheless, Pfizer performed a lower EV-to-EBITDA 
from 2017 till 2020, which indicates that the company is undervalued in comparison to 
its main competitors. This is a good sign for the company mainly due to the fact that an 
undervalued company is expected to exhibit a higher value in the future, whereas an 






9. Long term trends 
9.1 Total asset turnover 
Concerning the total asset turnover, its purpose is to measure “how all assets owned by a 
company are operated” (Nurlaela et al., 2019) in order to support the revenues of the 
company. In this case, we can clearly see that Pfizer follows the same trend as the 
pharmaceuticals & biotechnology sector, as we can see in the Figure 15 below. However, 
we also must concede the fact that Pfizer´s total asset turnover has always been less than 
the average of their competitors. This indicates that Pfizer is less efficient when it comes 
to exploiting their assets in order to stimulate their sales. 
Figure 15: Total Asset Turnover Pfizer vs Pharmaceutical & Biotechnology sector 
 
Source: Calculation from Pfizer´s Financial Statements 
9.2 Current Ratio 
Regarding Pfizer´s current ratio, we can state that the company is exhibiting a lot of 
volatility when it comes to its liquidity. To be more exact, Pfizer in general terms shows 
a higher current ratio from 2005 till 2014 than the average of the pharmaceuticals & 
biotechnology sector, whereas from 2015 till 2020 it showcases a lower current ratio than 
its competitors. Nevertheless, this is about to change, given the fact that Pfizer is 
displaying an increase in this ratio from 2019 onwards, because they reduced their short-
term debt by 30,52% from 2019 to 2020, while their competitors are displaying a 
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that Pfizer has been able to cover their current liabilities with their current assets during 
the last 15 years due to the fact that the ratio has always been above 1, which indicates 
higher liquidity (Fight, 2005). However, it is also true that they have experienced a decline 
from 2015 onwards, which is a bad sign, given the fact that a lower ratio implies less 
security “that the retirement of current liabilities may be made” (Mellen & Evans, 2018). 
Figure 16: Current Ratio Pfizer vs Pharmaceutical & Biotechnology sector 
 
Source: Calculation from Pfizer´s Financial Statements 
9.3 Debt to Equity 
Next, we will analyze the debt-to-equity ratio. The first thing to point out is that Figure 
17 illustrates Pfizer´s lower debt to equity ratio in comparison to the pharmaceuticals and 
biotechnology sector. Here, we must acknowledge that Pfizer is less leveraged than their 
average competitors, given the fact that their debt-to-equity ratio is below the sector´s 
average ratio from 2011 onwards. This means that Pfizer cannot accelerate as many 
financial objectives through debt as their average competitor, because they will have less 
access to cash in order to invest in more assets. Nevertheless, we must take into account 
both sides of the same coin. Having less leverage is also a good sign for the company´s 
reputation, “because this reduces the probability of bankruptcy and thus reduces the 
likelihood that management will suffer a loss of reputation associated with controlling a 
bankrupt firm” (Eckbo, 2008). In other words, it is more likely to trust Pfizer than most 
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Figure 17: Debt-to-Equity Pfizer vs Pharmaceutical & Biotechnology sector 
 
Source: Calculation from Pfizer´s Financial Statements 
9.4 Net Profit Margin 
With reference to Pfizer´s net profit margin, we can clearly see that overall they have 
exhibited higher figures in the last 15 years with respect to not only their pharmaceuticals 
& biotechnology sector competitors, but also their health industry competitors. In 
addition to that, we can see in both Figures 18 and 19 that even though Pfizer is 
showcasing high volatility in their figures, they are still able to surpass their competitors 
overall during these last 5 years. These are positive signs for the company because it 
proves that they are more flexible in dealing with their expenses than their competition. 
As a matter of fact, as mentioned before, Pfizer has suffered a revenue reduction of 
19,02% in 2020, which was significantly more than their industry competitors, but they 
still managed to achieve a higher net profit margin than the industry average due to their 
flexibility handling costs. This proves that Pfizer has a competitive advantage when it 
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Figure 18: Net Profit Margin Pfizer vs Pharmaceutical & Biotechnology sector 
 
Source: Calculation from Pfizer´s Financial Statements 
Figure 19: Net Profit Margin Pfizer vs Health Care Industry 
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9.5 Price to Earnings 
Next, we must analyze Pfizer´s price to earnings6, given the fact that this ratio explains 
the company´s “current market valuation of a company, relative to its earnings” 
(Schmidlin, 2014). The first thing to acknowledge is that Pfizer generally is performing 
a lower price-to-earnings ratio than their average competitors during the last 15 years, 
except for the time period of 2009 till 2010 and 2014 to 2016. In addition to that, we can 
claim by viewing Figure 20, that the pharmaceuticals & biotechnology sector as a whole 
is showing quite a lot of volatility. With respect to that, a “common thumb rule in Wall 
Street is that the growth rate ought to be roughly equal to the P/E ratio” (Kumar, 2015). 
Therefore, this means that Pfizer is viewed as a riskier company in comparison to its 
average sector competitors because its price-to-earnings rate is below the average of the 
pharmaceuticals & biotechnology sector, which usually indicates a lower growth rate for 
the company than its competition. 
Figure 20: Price-to-Earnings Pfizer vs Pharmaceutical & Biotechnology sector 
 
Source: Calculation from Pfizer´s Financial Statements 
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9.6 Price to sales 
Regarding the enterprise´s price-to-sales ratio7, we can state the fact that Pfizer is 
accomplishing very similar results that are slightly below the figures from their average 
sector competitors from the pharmaceuticals & biotechnology sector in the last 15 years. 
The main reason to analyze this ratio is because it “measures how much an investor is 
willing to pay for each dollar of sales. “(Vruwink et al., 2011), in other words, it helps to 
determine whether a share is cheap or expensive. In this case, unlike the price-to-earnings 
ratio from the prior section, the entire sector showcases a positive trend since 2008. To 
be exact, Pfizer has increased from a value of 1,72 in 2008 to 4,5 in 2020, to put it in 
another way, the value of the price-to-sales ratio has almost increased by 3 in 12 years. 
Therefore, we can claim that Pfizer´s and their competitors´ price-to-sales have increased 
significantly because the investors expect the sector to become considerately more 
relevant in the future. To be more precise, it is no surprise that the price-to-sales ratio is 
as high as it has ever been because of the Covid-19 pandemic, henceforth we can expect 
Pfizer to attain an even better result for their price-to-sales ratio for the time ahead. 
Figure 21: Price-to-Sales Pfizer vs Pharmaceutical & Biotechnology sector 
 
Source: Calculation from Pfizer´s Financial Statements 
 
                                                             









Pfizer Inc. Pharmaceuticals & Biotechnology
47 
 
9.7 Price to book value 
Lastly, we are going to examine Pfizer´s price-to-book-value 8. Regarding the book value 
per share, it is the amount that would remain “if the company liquidated all of its assets 
and repaid its liabilities” (CFI, 2021) divided by the total number of common stock 
outstanding. The first thing to notice when evaluating Figure 22 is that Pfizer´s price-to-
book value ratio is clearly lower than the pharmaceuticals & biotechnology sector from 
2005 till 2020. This is not a good sign for the company, given the fact that they are 
displaying clearly worse results than their competition. With respect to that, a “higher P/B 
ratio reflects expected future prospects on account of perceived growth opportunities or 
competitive advantages” (Kumar, 2015). Nevertheless, this statement does not reflect 
Pfizer´s situation, because they clearly underperformed when we compare their figures to 
their competitors. To be more precise, Pfizer has only increased from a value of 2,94 to 
2,98 in 15 years, whereas the average of the pharmaceuticals & biotechnology sector has 
been able to increase from a value of 4,09 to 6,78 in the same time span. That is why we 
can assert the fact that Pfizer is predicted to be less likely to have better growth 
opportunities than their competition.  
Figure 22: Price-to-Book Value Pfizer vs Pharmaceutical & Biotechnology sector 
 
Source: Calculation from Pfizer´s Financial Statements 
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In summary, Pfizer is less efficient when it comes to the exploitation of assets in 
comparison to its competitors, due to a lower asset turnover in the last 15 years. 
Furthermore, the company also exhibits a lower current asset ratio from 2014 to 2020, 
which can be a sign of less security. Nevertheless, Pfizer is a company that prioritizes 
security over anything else because they showcase a lower debt-to-equity ratio in order 
to prevent the chance of bankruptcy. Moreover, Pfizer has overall performed better results 
in its net profit margin than its competitors over the last 15 years, which proves that the 
company is very flexible when it comes to dealing with its expenses. 
10. Valuation in 5 years 
One thing that is certain is that the pharmaceutical industry will grow inevitably due to 
the health crisis. Therefore, we can claim that Pfizer has a good potential to grow 
significantly in the time to come, nonetheless, the future is unpredictable. For this reason, 
the paper is going to estimate a moderate, negative, and positive scenario in 5 years for 
the company. 
10.1 Beta Estimation 
Regarding Pfizer´s future valuation, we need to calculate its beta. The chosen beta will 
be calculated based on the S&P 500 stock market, which is an index of the most important 
“500 widely held stocks on the New York Stock Exchange (NYSE) and NASDAQ” 
(DeChesare, 2016). With respect to the variance and the covariance, I have used the 
potential future exposure of the last 59 months, to be more specific from the 29th of 
February 2016 till 31st of December 2020. The purpose of the beta is “a measurement of 
the volatility of a given security in comparison to the volatility of the market as a whole, 
which is known as systematic risk” (Mellen & Evans, 2018). In case the beta is negative, 
this would imply that investors prefer to buy stock when market prices are falling 
(Mascareñas, J., 2019). However, this is not the case because our calculated beta gives us 
a value of 0,639. This implies that Pfizer´s beta is less risky because a “beta of less than 
1 means that the security will be less volatile than the market” (Kumar, 2015). However, 
this also indicates that Pfizer´s lower beta “will likely offer low returns as well” (Booker, 
2021).  
                                                             
9 We calculate the beta by dividing the covariance of the S&P 500 by the variance of the S&P 500 
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Table 27: Beta based on the S&P 500 stock market 
Variance(S&P 500)10 19,02 
Covariance(PFE, S&P 500)11 11,94 
β(PFE) 0,63 
Source: Calculation from Pfizer´s Financial Statements 
10.2 Weighted Average Cost of Capital 
The next important tool in order to calculate Pfizer´s value is to discount the free cash 
flows by “using the weighted average cost of debt and equity or weighted average cost of 
capital (WACC)” (Fernandez, 2002). In order to calculate the WACC, we must “use as 
weights debt’s and equity’s respective contribution to the company’s total amount of 
funds” (Massari et al., 2016). In this case, we employed both Pfizer´s equity and debt at 
their fair value. Next, we multiply the given weights by their respective required rates of 
return and sum both results, which inevitably gives us a WACC of 7,10%.  
Table 28: WACC 
  Value Weight Required rate of return 
Equity 188.87012  0,83 7,98% 
Preferred stock 
(book value) — — — 
Debt 39.83613  0,17 2,89%14 
WACC     7,10% 




                                                             
10 “VarianceS&P 500 = Σ(RS&P 500,t–RS&P 500)2 ÷ (59 – 1)” (Stock Analysis, 2021) 
11 “CovariancePFE, S&P 500 = Σ(RPFE,t–RPFE)×(RS&P 500,t–RS&P 500) ÷ (59 – 1)” (Stock Analysis, 2021) 
12 In millions of US dollars 
13 In millions of US dollars 
14 Weighted average interest rate*(1- Estimated average effective income tax rate) 
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Table 29: Required Rate of Return 
Rate of return on LT Treasury     R(F) 1,25%15 
Expected rate of return on market portfolio E[R(M)] 11,98%16 
Systematic risk of Pfizer Inc.’s common stock β(PFE) 0,63 
Required rate of return on Pfizer Inc.’s common stock17 r(PFE) 7,98% 
Source: Calculation from Pfizer´s Financial Statements 
Table 30: Weighted Average Interest Rate 
Weighted average interest rate 3,10% 
Source: Finbox 
Table 31: Required Rate of Return 
 2016 2017 2018 2019 2020 
Annual Effective Income Tax Rate 13,45% 0% 5,94% 7,83% 6,36% 
Estimated average effective income tax rate         6,72% 
Source: CSI Market 
 
10.3 Moderate, Negative and Positive Scenario 
Next, we will analyze Pfizer´s different growths till the year 2025. In order to do this, we 
must estimate the future free cash flows by using three different values, namely the last 
FCFF of 2020 with a value of $9421 million, the WACC at a rate of 7,10%, and the 
respective growth rates depending on the type of scenario. With the aim of calculating 
the value of the company, we will employ the discounted cash flow method, which “uses 
future free cash flow (FCF) projections and discount the cash flow to get the present value 
that can be used to estimate the potential for investment.” (Kumar, 2015). Regarding that, 
the calculation is based on the discounted cash flow method from Kumar´s Book 
“Valuation Theories and Concepts” and it works as follows: 
                                                             
15 Rate of return on Long term Treasury according to Statista 
16 Expected rate of return on market portfolio according to Yahoo.Finance of the S&P 500 
















Regarding the moderate scenario, the chosen value is a constant growth rate of 3,5%. The 
main reason that the moderate growth rate is 3,5%, is because of the fact that even though 
Pfizer has increased in popularity and has good growth expectations, we must also take 
into consideration that there are several factors that hinder their growth in the future, such 
as “waiving patent protections” (Macias et al., 2021), due to the COVID-19 pandemic. 
The first step to calculate Pfizer´s price per share is to sum the future cash flows as well 
as the terminal value and discount them to their present value (Glantz, 2014), which gives 
us $271.149 million. The next step is to deduct the preferred stock at its book value and 
the company´s debt at its fair value, which is a result of $231.313 million.  The last step 
is to divide the future value of Pfizer’s common stock by the total number of shares18. 
The result is a share price of $41,47, which is higher than the current price per share on 
May 21st, 2021 with a value of $39,95 per share. 
Concerning the negative scenario, the selected rate is a constant growth value of 2,5%, 
mainly due to fiercer competition. For example, the vaccine competitors are rising over 
time, which will lead to higher worldwide production and as a result more variety for 
customers, in other words, Pfizer´s market share for COVID-19 usage will decrease. In 
this case, Pfizer´s intrinsic value of capital would be $210.103 million, which is an 
approximate difference of $51.676 million in comparison to the moderate scenario. In 
addition to that, once we reduce the preferred stock at its book value and the company´s 
debt at its fair value, the end result of Pfizer´s intrinsic common stock value would be 
$170.267 million, which will result in a price of $30,53 per share. 
Lastly, we must analyze the positive scenario. In this case, the selected value is going to 
be a constant growth rate of 4,5%. The primary reason for this value, is because Pfizer is 
very likely to persevere in the production and quality of their Covid-19 vaccine, unlike 
some of their competitors. For example, the European Union has decided “not to renew 
AstraZeneca vaccines contract” (Churm, 2021) after June, because several countries 
claimed that this vaccine was not efficient enough. When taking a closer look at Pfizer´s 
                                                             
18 I have used the last available number of shares of the 31st of December 2020 
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intrinsic value of capital, we can clearly see that they would exhibit their highest figure 
so far with a value of $379.223 million. The next step consists of deducting the preferred 
stock at its book value and the company´s debt at its fair value, which gives us an intrinsic 
value of the common stock of $339.387 million and consequently a price of $60,85 dollars 
per share.  
Table 32: All possible Scenarios 
Moderate Intrinsic value of Pfizer’s common stock (per share) $41,47 
Negative Intrinsic value of Pfizer’s common stock (per share) $30,53 
Positive Intrinsic value of Pfizer’s common stock (per share) $60,85 
Source: Calculation from Pfizer´s Financial Statements 
 
Table 33: Moderate Scenario  
Year     Value FCFF(t) or TV(t) Present value at 
7.10% 
0 FCFF(0) 9421   
1 FCFF(1) 9751 9105 
2 FCFF(2) 10092 8799 
3 FCFF(3) 10445 8503 
4 FCFF(4) 10811 8218 
5 FCFF(5) 11189 7942 
5 TV(5) 322040 228582 
Intrinsic value of Pfizer Inc.’s capital 271.149  
Less: Preferred stock, no par value, at stated value (book 
value) — 
Less: Debt (fair value) 39.836  
Intrinsic value of Pfizer Inc.’s common stock 231.313  
      
Intrinsic value of Pfizer Inc.’s common stock (per share) $41,47 
Current share price $39,95 
 









Table 34: Negative Scenario  
Year     Value FCFF(t) or TV(t) Present value at 
7.10% 
0 FCFF(0) 9421   
1 FCFF(1) 9657 9017 
2 FCFF(2) 9898 8630 
3 FCFF(3) 10145 8259 
4 FCFF(4) 10399 7905 
5 FCFF(5) 10659 7566 
5 TV(5) 237713 168727 
Intrinsic value of Pfizer Inc.’s capital 210.103  
Less: Preferred stock, no par value, at stated value (book 
value) — 
Less: Debt (fair value) 39.836  
Intrinsic value of Pfizer Inc.’s common stock 170.267  
        
Intrinsic value of Pfizer Inc.’s common stock (per share) $30,53 
Current share price $39,95 
 
Source: Calculation from Pfizer´s Financial Statements 
 
Table 35: Positive Scenario  
Year     Value FCFF(t) or TV(t) Present value at 
7.10% 
0 FCFF(0) 9421   
1 FCFF(1) 9845 9193 
2 FCFF(2) 10288 8970 
3 FCFF(3) 10751 8752 
4 FCFF(4) 11235 8540 
5 FCFF(5) 11740 8333 
5 TV(5) 472581 335435 
Intrinsic value of Pfizer Inc.’s capital 379.223  
Less: Preferred stock, no par value, at stated value (book 
value) — 
Less: Debt (fair value) 39.836  
Intrinsic value of Pfizer Inc.’s common stock 339.387  
        
Intrinsic value of Pfizer Inc.’s common stock (per share) $60,85 
Current share price $39,95 





10.4 Sensitivity Analysis 
Lastly, we will examine Pfizer´s sensitivity analysis, in order to find out “the 
mathematical change in the final result when there is a variation in one of the key variables 
underlying the cash flow forecast” (Massari et al., 2016). Concerning the growth rate of 
the enterprise, it is most likely to be between 2,5% and 4,5%, due to the three possible 
scenarios described before in section 10.3. In addition to that, the company´s WACC will 
be between 6% and 8%, due to the fact that Pfizer Inc. have exhibited very similar results 
with very low fluctuations in terms of their debt-to-equity ratio during the last 5 years. In 
other words, the firm´s debt and equity weighs will remain very similar, which implies 
that the WACC is not going to change a lot for the time to come. Regarding Table 36, it 
highlights a green area that reflects the possible results for Pfizer´s intrinsic value of 
capital. In this case, when we analyze the green area, we can see that Pfizer would 
accomplish their best possible result when their WACC is at 6% and the growth rate at 
4,5%. However, the worst possible result would be when the enterprise experiences a 
WACC of 8% and a growth rate of 2,5%. That is to say, the lower the company´s WACC 
and the higher their growth rate, the higher Pfizer´s intrinsic value of capital will become. 
Table 36: Sensitivity Analysis  
      Wacc     









2% 166.505 157.769 149.500 141.667 134.244 
2,5% 190.263 180.436 171.135 162.326 153.980 
3% 219.826 208.638 198.051 188.027 178.530 
3,5% 257.615 244.686 232.453 220.873 209.904 
4% 307.614 292.379 277.967 264.325 251.407 
4,5% 376.880 358.446 341.012 324.513 308.891 
5% 479.199 456.038 434.135 413.412 393.794 
5,5% 645.636 614.779 585.604 558.005 531.882 
 








11. Real Valuation vs Market Valuation 
Another key aspect to analyze is to compare Pfizer´s market valuation shown on the New 
York Stock Exchange and the real valuation calculated before in section 10.3. The main 
reason for that is to determine whether the company´s stock “is under- or overvalued in 
order to facilitate” (Kumar, 2015) the company´s long-term investment strategy. In this 
case, it is important to emphasize the fact that Pfizer´s market valuation on May 21st is 
39,95 dollars per share, however, this is susceptible to change in the future. Moreover, 
we are going to employ the real valuation calculated in the moderate scenario and not in 
the negative or positive one, mainly due to the fact that it is the most likely foreseeable 
future. With respect to that, the value of the real valuation is going to be 41,47 dollars per 
share in 5 years, which is $1,52 more than Pfizer´s market valuation. Therefore, we can 
state that Pfizer´s value per share is slightly undervalued, hence it is recommended to buy 
the company´s stock in the upcoming future.  





It is important to emphasize the fact that, due to the distinctive features of the 
pharmaceuticals & biotechnology sector, and especially when it comes to a company like 
Pfizer that has significantly increased in popularity in the last months because of their 
COVID-19 vaccine, the value of the enterprise is susceptible to change. The main 
problem is that there is a high chance of a fluctuation in value caused by new information 







This academic paper has analyzed the valuation of the American company Pfizer Inc., one 
of the most important enterprises up to date that has proven to be key in order to restore 
the world back to normal through their COVID-19 vaccine. 
After performing an entire financial analysis of Pfizer´s financial statements, we can all 
agree that the company is less risky than their main competitors in the pharmaceuticals & 
biotechnology sector. This is mainly because they finance themselves less through debt, 
plus they continuously showcase better net profits than their competitors year after year. 
When it comes to the valuation of the company, we have calculated three possible 
scenarios, namely a positive, negative, and moderate one. According to that, after 
analyzing all three possibilities, we have come to the conclusion that the scenario most 
likely to happen is the moderate scenario with a value of 41,47 dollars per share, which 
has proven to be more than the company´s current market value on May 21st, 2021. 
Nonetheless, the value of the enterprise is susceptible to change on a daily basis because 
of new information that affects the pharmaceutical industry and consequently Pfizer as 
well. 
In conclusion, based on our analysis, ceteris paribus, Pfizer´s real valuation is slightly 
undervalued compared to its current market value, and therefore we recommend 














 Daft, R. and Armstrong, A., 2008. Organization theory and design. 10th ed. 
Cengage Learning 
 Eckbo, BE (ed.) 2008, Handbook of Empirical Corporate Finance SET, Elsevier 
Science & Technology, Burlington. Available from: ProQuest Ebook Central 
 Fernandez, P 2002, Valuation Methods and Shareholder Value Creation, Elsevier 
Science & Technology, San Diego. Available from: ProQuest Ebook Central.  
 Fight, A 2005, Cash Flow Forecasting, Elsevier Science & Technology, Oxford. 
Available from: ProQuest Ebook Central.  
 Glantz, M 2014, Navigating the Business Loan : Guidelines for Financiers, Small-
Business Owners, and Entrepreneurs, Elsevier Science & Technology, San Diego. 
Available from: ProQuest Ebook Central. 
 Hollensen, S., 1998. Global marketing. 6th ed. Pearson. 
 Kumar, R 2015, Valuation : Theories and Concepts, Elsevier Science & 
Technology, San Diego. Available from: ProQuest Ebook Central. 
 Marburger, D 2012, How Strong Is Your Firm's Competitive Advantage?, 
Business Expert Press, New York. Available from: ProQuest Ebook Central.  
 Mascareñas Pérez-Iñigo, J. (2019) Fusiones, adquisiciones y valoración de 
empresas. 6ª edn. Madrid: Ecobook. 
 Massari, M, Gianfrate, G, & Zanetti, L 2016, Corporate Valuation : Measuring 
the Value of Companies in Turbulent Times, John Wiley & Sons, Incorporated, 
Somerset. Available from: ProQuest Ebook Central. 
 McGowan, C, Gardner, JC, & Moeller, SE 2015, The Fundamentals of Financial 
Statement Analysis As Applied to the Coca-Cola Company, Business Expert 
Press, New York. Available from: ProQuest Ebook Central.  
 Mellen, CM, & Evans, FC 2018, Valuation for M&a : Building and Measuring 
Private Company Value, John Wiley & Sons, Incorporated, Newark. Available 
from: ProQuest Ebook Central.  
 Ross, S., Westerfield, R. and Jordan, B., 1991. Fundamentals of corporate 
finance. 9th ed. Boston. 
58 
 
 Schmidlin, N 2014, The Art of Company Valuation and Financial Statement 
Analysis : A Value Investor's Guide with Real-Life Case Studies, John Wiley & 
Sons, Incorporated, New York. Available from: ProQuest Ebook Central. 
 
14.2 Journals: 
 Affandi, F., Sunarko, B. and Yunanto, A., 2019. The Impact of Cash Ratio, Debt 
To Equity Ratio, Receivables Turnover, Net Profit Margin, Return On Equity, and 
Institutional Ownership To Dividend Payout Ratio. JOURNAL OF RESEARCH 
IN MANAGEMENT, 1(4) 
 Evans, G. and Neu, C., 2008. The Use of Strategic Forces to Understand 
Competitive Advantages Provided by Information Technology. Journal of 
International Technology and Information Management, 17(2).  
 Gathu, K., 2018. Influence of cash flows from investing activities on Shareholders 
Returns among Manufacturing and Allied Companies Listed in the Nairobi 
Securities bourse, Kenya. Supreme Journal of Business Management, 1(1), pp.26-
41. 
 Kasapi, Z. and Mihiotis, A., 2011. Management as applied to New Products 
Penetration in the Competitive Environment of Pharmaceutical 
Industry. Interdisciplinary Journal of Research in Business, [online] 1(Issue. 10), 
pp.(pp.73- 85). Available at: 
<https://citeseerx.ist.psu.edu/viewdoc/download?doi=10.1.1.736.3250&rep=rep
1&type=pdf>. 
 Kumazawa, R., 2017. Patenting in the Pharmaceutical Industry. Intellectual 
Property Rights,. 
 Malingu Achode, B. and Rotich, G., 2016. Effects of accounts Payable as Source 
of Financing on Performance of Listed Manufacturing Firms at the Nairobi 
Securities Exchange. International Journal of Research Studies in Agricultural 
Sciences, [online] 2(4). Available at: <https://www.arcjournals.org/pdfs/ijrsas/v2-
i4/3.pdf>. 
 Nurlaela, S., Mursito, B., Kustiyah, E., Istiqomah, I. and Hartono, S., 2019. 
ASSET TURNOVER, CAPITAL STRUCTURE AND FINANCIAL 
PERFORMANCE CONSUMPTION INDUSTRY COMPANY IN INDONESIA 
59 
 
STOCK EXCHANGE. International Journal of Economics and Financial Issues, 
9(3), pp.297-301.  
 Scott Morton, F., 2000. Barriers to entry, brand advertising, and generic entry in 
the US pharmaceutical industry. International Journal of Industrial Organization, 
18(7), pp.1085-1104. 
 Stedeford, T., 2009. Patents. Information Resources in Toxicology, pp.711-716. 
 Vruwink, D., Quirin, J. and O'Bryan, D., 2011. A Modified Price-Sales Ratio: A 
Useful Tool For Investors?. Journal of Business & Economics Research (JBER), 
5(12). 
14.3 Websites 
 Armstrong, M., 2021. Acceso Web Unificado a la UCM (Web SSO). [online] 
Www-statista-com.bucm.idm.oclc.org. Available at: https://www-statista-
com.bucm.idm.oclc.org/chart/24390/public-safety-perceptions-covid-vaccines/  
 Berman, K. and Knight, J., 2009. When Is Debt Good?. [online] Harvard Business 




 Booker, R., 2021. What Does Low Beta Mean for a Business?. [online] Small 
Business - Chron.com. Available at: https://smallbusiness.chron.com/low-beta-
mean-business-26280.html  
 Bragg, S., 2021. Asset to equity ratio — AccountingTools. [online] 
AccountingTools. Available at: https://www.accountingtools.com/articles/the-
asset-to-equity-ratio.html  
 Bragg, S., 2020. Equity turnover definition — AccountingTools. [online] 




 Bremmer, I., 2020. The Next Global Depression Is Coming and Optimism Won’t 
Slow It Down. [online] Time. Available at: https://time.com/5876606/economic-
depression-coronavirus/   
60 
 
 CDC, 2021. Understanding mRNA COVID-19 Vaccines. [online] Centers for 
Disease Control and Prevention. Available at: 
https://www.cdc.gov/coronavirus/2019-ncov/vaccines/different-
vaccines/mrna.html  
 CFI, 2021. Cash Flow from Financing Activities - Overview, Examples, What's 
Included. [online] Corporate Finance Institute. Available at: 
https://corporatefinanceinstitute.com/resources/knowledge/accounting/cash-
flow-from-financing-activities/  
 CFI, 2021. Debt to Asset Ratio - How to Calculate this Important Leverage Ratio. 
[online] Corporate Finance Institute. Available at: 
https://corporatefinanceinstitute.com/resources/knowledge/finance/debt-to-asset-
ratio/  
 CFI, 2021. Free Cash Flow (FCF) - Most Important Metric in Finance & 
Valuation. [online] Corporate Finance Institute. Available at: 
https://corporatefinanceinstitute.com/resources/knowledge/valuation/what-is-
free-cash-flow-fcf/  
 CFI, 2021. Market to Book Ratio (Price to Book) - Formula, Examples, 
Interpretation. [online] Corporate Finance Institute. Available at: 
https://corporatefinanceinstitute.com/resources/knowledge/valuation/market-to-
book-ratio-price-book/  
 CFI, 2021. Operating Profit Margin - Learn to Calculate Operating Profit 





 CFI, 2021. Share Repurchase - Overview, Impact, and Signaling Effect. [online] 
Corporate Finance Institute. Available at: 
https://corporatefinanceinstitute.com/resources/knowledge/finance/share-
repurchase/  
 CSI Market, 2021. Abbott Laboratories Comparisons to its Competitors, Market 
share and Competitiveness by Segment - CSIMarket. [online] Csimarket.com. 
Available at: https://csimarket.com/stocks/compet_glance.php?code=ABT  
61 
 
 CSIMarket, 2021. Pfizer Inc Comparisons to its Competitors, Market share and 
Competitiveness by Segment - CSIMarket. [online] Csimarket.com. Available at: 
https://csimarket.com/stocks/compet_glance.php?code=PFE  
 Churm, P., 2021. European Union opts not to renew AstraZeneca vaccines 
contract. [online] euronews. Available at: 
https://www.euronews.com/2021/05/09/european-union-opts-not-to-renew-
astrazeneca-vaccines-contract-after-supply-rowDeChesare, B., 2016. [online] 
Mergersandinquisitions.com. Available at: 
https://www.mergersandinquisitions.com/what-is-the-sp-500/  
 EFPIA, 2020. The Pharmaceutical Industry in Figures. [online] Efpia.eu. 
Available at: https://efpia.eu/media/554521/efpia_pharmafigures_2020_web.pdf  
 FDA, 2021. Generic Drug Facts. [online] U.S. Food and Drug Administration. 
Available at: https://www.fda.gov/drugs/generic-drugs/generic-drug-facts   
 Finbox, 2021. The Complete Toolbox for Investors | finbox.com. [online] 
Finbox.com. Available at: https://finbox.com/NYSE:PFE/models/wacc  
 Fin-Wiser Advisory, 2018. [online] Fin-wiser.com. Available at: http://fin-
wiser.com/wp-content/uploads/2018/10/Enterprise-Value-Analysis.pdf  
 Fosher, H., 2018. Understanding the Marketing and Management of trails using 
PESTEL Analysis. [online] Available at: 
https://scholars.unh.edu/cgi/viewcontent.cgi?article=2182&context=thesis  
 Fredman, J., 2021. When Would You Say No to a Higher ROI?. [online] Small 
Business - Chron.com. Available at: https://smallbusiness.chron.com/would-say-
higher-roi-66551.html  
 Grand View Research, 2021. Pharmaceutical Manufacturing Market Size Report, 







y%202027.    
62 
 
 HealthCare.gov, 2021. Brand Name (Drugs) - HealthCare.gov Glossary. [online] 
HealthCare.gov. Available at: https://www.healthcare.gov/glossary/brand-name-
drugs/#:~:text=A%20drug%20sold%20by%20a,is%20protected%20by%20a%2
0patent.   
 IQVIA, 2021. Global Medicine Spending and Usage Trends. [online] 
Heatinformatics.com. Available at: 
https://heatinformatics.com/sites/default/files/images-videosFileContent/iqvia-
institute-global-medicines-and-usage-trends-to-2025-0421-forweb.pdf  
 Kasi, A., 2017. Porter Five Forces Analysis of US Pharmaceutical 






 Katella, K., 2021. Comparing the COVID-19 Vaccines: How Are They Different?. 
[online] Yale Medicine. Available at: https://www.yalemedicine.org/news/covid-
19-vaccine-comparison  
 Liu, M., 2021. Why the Johnson & Johnson vaccine is more effective than you 
think. [online] URMC Newsroom. Available at: 
https://www.urmc.rochester.edu/news/story/why-the-johnson-johnson-vaccine-
is-more-effective-than-you-think  
 Loughran, T. and Wellman, J., 2009. [online] Csinvesting.org. Available at: 
http://csinvesting.org/wp-content/uploads/2012/05/enterprise-multiple-vs-tobins-
q.pdf  
 Macias, A., Breuninger, K. and Franck, T., 2021. U.S. backs waiving patent 
protections for Covid vaccines, citing global health crisis. [online] CNBS. 
Available at: https://www.cnbc.com/2021/05/05/us-backs-covid-vaccine-
intellectual-property-waivers-to-expand-access-to-shots-worldwide.html  
 MarketScreener, 2021. Pfizer : 2020 ESG Report | MarketScreener. [online] 





 Mogalian, E. and Myrdal, P., 2021. What's the difference between brand-name 
and generic prescription drugs?. [online] Scientific American. Available at: 
https://www.scientificamerican.com/article/whats-the-difference-betw-2004-12-
13/  
 Pfizer, 2021. [online] Pfizer´s ANNUAL REPORT. Available at: 
https://d18rn0p25nwr6d.cloudfront.net/CIK-0000078003/9353920d-d7a2-4609-
9685-f302fe931480.pdf  
 Pfizer, 2021. [online] FORM 10-K. Available at: 
https://d18rn0p25nwr6d.cloudfront.net/CIK-0000078003/9353920d-d7a2-4609-
9685-f302fe931480.pdf   
 Pfizer, 2021. Pfizer Completes $1.25 Billion Sustainability Bond for Social and 




 Raza, W., Grumiller, J., Grohs, H., Essletzbichler, J. and Pintar, N., 2021. Post 
Covid-19 value chains: options for reshoring production back to Europe in a 
globalised economy. [online] Europarl.europa.eu. Available at: 
https://www.europarl.europa.eu/RegData/etudes/STUD/2021/653626/EXPO_ST
U(2021)653626_EN.pdf  
 Richards, V. and Laughlin, E., 1980. A Cash Conversion Cycle Approach to 




 Smith, J., 2021. Here’s How the AstraZeneca COVID-19 Vaccine Compares to 
Those Available in the U.S.. [online] Prevention. Available at: 
https://www.prevention.com/health/a35118263/astrazeneca-vs-pfizer-vs-
moderna-covid-19-vaccine/  
 Stock Analysis, 2021. Pfizer Inc. (NYSE:PFE) | CAPM. [online] Stock Analysis 




 Young, S., 2020. How to Finance Growth Through VC Funding and/or Debt - 
Pollen VC Insights. [online] Pollen.vc. Available at: https://pollen.vc/blog/how-
to-finance-growth-through-vc-funding-or-debt/  



























15.1 Appendix 1: Income Statement 
 
2016 2017 2018 2019 2020 
Revenues 52,824 52,546 53,647 51,750 41,908 
Cost of sales (12,329) (11,240) (11,248) (10,219) (8,692) 
Gross profit 40,495 41,306 42,399 41,531 33,216 
Selling, informational and administrative expenses (14,837) (14,784) (14,455) (14,350) (11,615) 
Research and development expenses (7,872) (7,657) (8,006) (8,650) (9,405) 
Amortization of intangible assets (4,056) (4,758) (4,893) (4,610) (3,436) 
Restructuring charges and certain acquisition-related costs (1,724) (487) (1,044) (747) (600) 
Operating income 12,006 13,620 14,001 13,174 8,160 
Gain on completion of Consumer Healthcare JV transaction — — — 8,086 6 
Interest income 470 391 333 226 73 
Interest expense (1,186) (1,270) (1,316) (1,574) (1,449) 
Net interest expense (716) (879) (983) (1,348) (1,376) 
Royalty-related income 905 499 495 648 770 
Net gains (losses) on asset disposals 171 343 71 31 (237) 
Net gains recognized during the period on equity securities — — 586 454 540 
Net realized losses on sales of investments in debt securities — — (141) — — 
Income from collaborations, out-licensing arrangements and 
sales of 
     
compound/product rights — — 488 168 326 
Net periodic benefit credits (costs) other than service costs — — 288 (64) 236 
Certain legal matters, net (510) (240) (157) (554) (28) 
Certain asset impairments (1,447) (395) (3,115) (2,843) (1,691) 
Business and legal entity alignment costs (261) (71) (4) (338) — 
Net losses on early retirement of debt (312) (999) (3) (138) — 
Consumer Healthcare JV equity method income — — — 17 298 
Other, net (1,485) 427 359 389 493 
Other income (deductions), net (3,655) (1,315) (2,116) (3,578) (669) 
Income from continuing operations before (provision) benefit 
for 
     
taxes on income 8,351 12,305 11,885 17,682 7,497 
(Provision) benefit for taxes on income (1,122) 9,048 (706) (1,384) (476) 
Income from continuing operations 7,229 21,353 11,179 16,298 7,021 
Income (loss) from discontinued operations, net of tax 16 (1) 9 4 2,631 
Gain on disposal of discontinued operations, net of tax 1 3 — — — 
Discontinued operations, net of tax 17 2 9 4 2,631 
Net income before allocation to noncontrolling interests 7,246 21,355 11,188 16,302 9,652 
Net income attributable to noncontrolling interests (31) (47) (35) (29) (36) 
Net income attributable to Pfizer Inc. 7,215 21,308 11,153 16,273 9,616 
Preferred stock dividends, net of tax (1) (1) (1) (1) — 














15.2 Balance Sheet 
       2016 2017          2018 2019 2020 
Cash and cash equivalents 2,595 1,342 1,139 1,305 1,784 
Short-term investments 15,255 18,650 17,694 8,525 10,437 
Trade accounts receivable, less allowance for doubtful accounts 8,225 8,221 8,025 8,724 7,930 
Inventories 6,783 7,578 7,508 8,283 8,046 
Current tax assets 3,041 3,050 3,374 3,344 3,264 
Other current assets 2,249 2,288 2,461 2,600 3,439 
Current assets of discontinued operations and other assets held for sale 801 12 9,725 22 167 
Current assets 38,949 41,141 49,926 32,803 35,067 
Equity-method investments — — 181 17,133 16,856 
Long-term investments 7,116 7,015 2,586 3,014 3,406 
Property, plant and equipment 13,318 13,865 13,385 13,967 13,900 
Identifiable intangible assets 52,648 48,741 35,211 35,370 28,471 
Goodwill 54,449 55,952 53,411 58,653 49,577 
Noncurrent deferred tax assets and other noncurrent tax assets 1,812 1,855 1,924 2,099 2,383 
Other noncurrent assets 3,323 3,228 2,798 4,450 4,569 
Noncurrent assets 132,666 130,656 109,496 134,686 119,162 
Total assets 171,615 171,797 159,422 167,489 154,229 
 2016 2017         2018 2019 2020 
Short-term borrowings, including current portion of long-term debt 10,688 9,953 8,831 16,195 2,703 
Trade accounts payable 4,536 4,656 4,674 4,220 4,309 
Dividends payable 1,944 2,029 2,047 2,104 2,162 
Income taxes payable 437 477 1,265 980 1,049 
Accrued compensation and related items 2,487 2,196 2,397 2,720 3,058 
Other current liabilities 11,023 11,116 10,754 11,085 12,639 
Liabilities held for sale — — 1,890 — — 
Current liabilities 31,115 30,427 31,858 37,304 25,920 
Long-term debt, excluding current portion 31,398 33,538 32,909 35,955 37,133 
Pension benefit obligations 6,406 5,926 5,272 5,638 4,766 
Postretirement benefit obligations 1,766 1,504 1,338 1,124 645 
Noncurrent deferred tax liabilities 30,753 3,900 3,700 5,578 4,063 
Other taxes payable 4,000 18,697 14,737 12,126 11,560 
Other noncurrent liabilities 6,337 6,149 5,850 6,317 6,669 
Noncurrent liabilities 80,660 69,714 63,806 66,738 64,836 
Total liabilities 111,775 100,141 95,664 104,042 90,756 
Preferred stock, no par value, at stated value 24 21 19 17 — 
Common stock, $0.05 par value 461 464 467 468 470 
Additional paid-in capital 82,685 84,278 86,253 87,428 88,674 
Treasury stock, shares at cost (84,364) (89,425) (101,610) (110,800) (110,98
8) 
Retained earnings 71,774 85,291 89,554 97,670 96,770 
Accumulated other comprehensive loss (11,036) (9,321) (11,276) (11,640) (11,688) 
Total Pfizer Inc. shareholders’ equity 59,544 71,308 63,407 63,143 63,238 
Equity attributable to noncontrolling interests 296 348 351 304 235 
Total equity 59,840 71,656 63,758 63,447 63,473 














15.3 Cash Flow Statement 
2016 2017 2018 2019 2020 
Net income before allocation to noncontrolling 
interests 
7,246 21,355 11,188 16,302 9,652 
Income from discontinued operations, net of tax — — — — (2,631) 
Net income from continuing operations before 
allocation to 
     
noncontrolling interests 7,246 21,355 11,188 16,302 7,021 
Depreciation and amortization 5,757 6,269 6,384 6,010 4,777 
Asset write-offs and impairments 1,613 634 3,398 2,953 2,049 
TCJA impact — (10,660) (596) (323) — 
Gain on completion of Consumer Healthcare JV 
transaction, net of 
     
cash conveyed — — — (8,233) (6) 
Deferred taxes from continuing operations (700) (2,410) (2,205) 614 (1,468) 
Share-based compensation expense 691 840 949 718 756 
Benefit plan contributions in excess of 
income/expense 
(712) (961) (1,095) (336) (1,790) 
Other adjustments, net 1,921 107 (1,270) (1,086) (478) 
Trade accounts receivable (134) 259 (644) (742) (1,249) 
Inventories 365 (357) (717) (1,050) (736) 
Other assets (60) (31) (16) 795 (146) 
Trade accounts payable 871 46 431 (564) 353 
Other liabilities (223) (67) 98 267 2,741 
Other tax accounts, net (734) 1,446 (78) (2,737) (1,238) 
Changes in assets and liabilities, net of 
acquisitions and 
     
divestitures 85 1,296 (926) (4,031) (275) 
Adjustments to reconcile net income before 
allocation to 
     
noncontrolling interests to net cash provided by 
operating 
     
activities 8,655 (4,885) 4,639 (3,714) 3,565 
Net cash provided by operating activities 15,901 16,470 15,827 12,588 10,586 
Purchases of property, plant and equipment (1,823) (1,956) (2,042) (2,176) (2,252) 
Purchases of short-term investments (15,957) (14,596) (11,677) (6,835) (13,805) 
Proceeds from redemptions/sales of short-term 
investments 
29,436 10,307 17,581 9,183 11,087 
Net (purchases of) proceeds from redemptions/sales 
of short-term 
     
investments with original maturities of three months 
or less 
(4,218) 2,058 (3,917) 6,925 920 
Purchases of long-term investments (8,011) (3,537) (1,797) (201) (597) 
Proceeds from redemptions/sales of long-term 
investments 
11,254 3,594 6,244 232 723 
Acquisitions of businesses, net of cash acquired (18,368) (1,000) — (10,861) — 
Acquisitions of intangible assets (176) (261) (154) (418) (539) 
Other investing activities, net 52 650 287 206 275 
Net cash (used in) provided by investing activities (7,811) (4,741) 4,525 (3,945) (4,188) 
Proceeds from short-term borrowings 7,472 8,464 3,711 16,455 12,352 
Principal payments on short-term borrowings (5,102) (9,990) (4,437) (8,378) (22,197) 
Net proceeds from (payments on) short-term 
borrowings with original 
     
maturities of three months or less (3,084) 1,401 (1,617) 2,551 (4,129) 
Proceeds from issuances of long-term debt 10,976 5,274 4,974 4,942 5,222 
Principal payments on long-term debt (7,689) (6,154) (3,566) (6,806) (4,003) 
Purchases of common stock (5,000) (5,000) (12,198) (8,865) — 
Cash dividends paid (7,317) (7,659) (7,978) (8,043) (8,440) 
Proceeds from exercise of stock options 1,019 862 1,259 394 425 
Other financing activities, net (196) (233) (589) (735) (870) 
Net cash used in financing activities (8,921) (13,035) (20,441) (8,485) (21,640) 
Net cash provided by operating activities from 
discontinued operations 
— — — — 3,817 
Net cash used in investing activities from 
discontinued operations 
— — — — (83) 
Net cash provided by financing activities from 
discontinued operations 
— — — — 11,991 
Net cash provided by discontinued operations — — — — 15,725 
Effect of exchange-rate changes on cash and cash 
equivalents and 
     
restricted cash and cash equivalents (215) 53 (116) (33) (8) 
Net increase (decrease) in cash and cash equivalents 
and restricted 
     
cash and cash equivalents (1,046) (1,253) (205) 125 475 
Cash and cash equivalents and restricted cash and 
cash equivalents, at 
     
beginning of period 3,641 2,595 1,430 1,225 1,350 
Cash and cash equivalents and restricted cash and 
cash equivalents, at 
     
end of period 2,595 1,342 1,225 1,350 1,825 
 
